

www.isheid.com

16th

isheid

HIV & Emerging Infectious Diseases
VIH & Maladies Infectieuses Emergentes

International Symposium
Symposium International

24 ▶ 26

March/Mars **2010**

Parc Chanot

Marseille, France



FINAL PROGRAMME
PROGRAMME FINAL

INDEX SOMMAIRE

Edito.....	p. 03
Committees.....	p. 03
Synopsis.....	p. 04
Wednesday 24 March / Mercredi 24 mars.....	p. 06
Thursday 25 March / Jeudi 25 mars.....	p. 09
Friday 26 March / Vendredi 26 mars.....	p. 13
Posters.....	p. 19
General Information / Informations générales.....	p. 39
Registration / Inscriptions.....	p. 40
Important dates / Dates importantes.....	p. 40
Sponsors / Partenaires.....	p. 41

Dear Sir/Madam,

On behalf of the Steering Committee for the 16th International Symposium on HIV & Emerging Infectious Diseases (ISHEID) to be held in Marseille (France), March 24-26, 2010, I have the pleasure to send you the advanced program of this meeting.

This edition of the ISHEID will attract numerous international experts from both the fields of HIV and other infectious diseases. The Steering Committee and the Scientific Committee have done their best to offer participants the most accurate information given by renowned leaders on the most interesting topics.

The quality of the scientific program and the originality of its themes have always been the hallmarks of the ISHEID; we will continue to follow the past successes, helped by the increased number of abstracts we received for this edition.

This year, the new location of Marseille allows better accommodation and accessibility than in the past: we hope that you will be part of this run-up!

See you in Marseille in March;

Alain Lafeuillade, MD

COMMITTEES

2010 Chairman

- ▶ Alain LAFEUILLADE (France)

2010 Steering Committee

- ▶ Jean-François DELFRAISSY (France)
- ▶ Jose GATELL (Spain)
- ▶ Guido POLI (Italy)
- ▶ Christine ROUZIOUX (France)
- ▶ Vicente SORIANO (Spain)
- ▶ Hans-J. STELLBRINK (Germany)
- ▶ Stefano VELLA (Italy)

2010 Scientific Committee

- ▶ Antoine CHERET (France)
- ▶ Patricia ENEL (France)
- ▶ Robert GALLO (USA)
- ▶ Gilles HITTINGER (France)
- ▶ Leondios KOSTRIKIS (Cyprus)
- ▶ John KALDOR (Australia)
- ▶ Denis LACOSTE (France)
- ▶ Mark NELSON (UK)
- ▶ Cecile POGGI (France)
- ▶ Isabelle POIZOT-MARTIN (France)
- ▶ Alain RIEU (France)
- ▶ Paolo RIZZARDI (Italy)
- ▶ Jurgen ROCKSTROH (Germany)
- ▶ Caroline SOLAS (France)
- ▶ Catherine TAMALET (France)
- ▶ Giuseppe TAMBUSI (Italy)
- ▶ Jean-Claude TARDY (France)



Mercredi 24 mars 2010

9h30	Auditorium	Amphithéâtre Callelongue
11h00	Session Plénière Maladies Infectieuses Emergentes	
11h30	Pause - café sponsorisée par Gilead	
13h00	Sessions Parallèles Gestion à Long Terme de l'Infection à VIH (I)	Sessions Parallèles VIH, Session Pharmacologique
14h00	Symposium Satellite de l'Industrie Schering Plough	Session COREVIH
15h30	Session Plénière Immunologie du VIH	
16h00	Pause - café sponsorisée par Gilead	
17h00	Conférence Plénière par Robert GALLO 25 Ans après avoir Découvert le VIH comme Agent Causal du SIDA : Recherche d'un Vaccin	
18h30	Symposium Satellite de l'Industrie - MSD Mettre le Cap sur de Nouvelles Stratégies	

Jeudi 25 mars 2010

8h30	Auditorium	Amphithéâtre Callelongue
10h30	Session Plénière Réservoirs du VIH & Primo-Infection	
11h00	Pause - café sponsorisée par Gilead	
12h30	Sessions Parallèles Résistances du VIH	Sessions Parallèles Présentations Orales Libres (I)
14h00	Symposium Satellite de l'Industrie Janssen-Cilag Changement de traitement antirétroviral chez les patients en succès virologique : quels risques, quels bénéfices ?	
15h30	Session Plénière Stratégies Antirétrovirales	
16h00	Pause - café sponsorisée par Gilead	
17h00	Conférence Plénière par Albert OSTERHAUS Le Défi Mondial des Maladies Emergentes	
18h30	Symposium Satellite de l'Industrie Abbot Virology Le VIH, une pathologie chronique : quelles priorités à prendre en charge ?	

Vendredi 26 mars 2010

8h30	Auditorium	Amphithéâtre Callelongue
10h30	Session Plénière Co-Infections	
11h00	Pause - café sponsorisée par Gilead	
12h30	Sessions Parallèles Patients VIH « Non Progresseurs »	Sessions Parallèles Présentations Orales Libres (II)
14h00	Sessions Parallèles Gestion à Long Terme de l'Infection à VIH (II)	Sessions Parallèles Posters Discutés
15h00	Sessions Parallèles Mise au Point d'un Vaccin contre le VIH	Sessions Parallèles « Post-CROI »
15h30	Pause - café sponsorisée par Gilead	
16h30	L'Essentiel du Symposium	

Wednesday 24 march 2010

9h30	Auditorium	Amphitheater Callelongue
11h00	Plenary Session Emerging Infectious Diseases	
11h30	Coffee break sponsored by Gilead	
13h00	Parallel Sessions Long Term HIV Management (I)	Parallel Sessions Pharmacology of HIV
14h00	Industry Satellite Symposium Schering Plough	Session COREVIH
15h30	Plenary Session Immunology of HIV	
16h00	Coffee break sponsored by Gilead	
17h00	Keynote Lecture by Robert GALLO 25 Years after Discovering HIV as the Cause of AIDS: Prospects for a Vaccine	
18h30	Industry Satellite Symposium - MSD Steering for New Strategies	

Thursday 25 march 2010

8h30	Auditorium	Amphitheater Callelongue
10h30	Plenary Session HIV Reservoirs & Primary Infection	
11h00	Coffee break sponsored by Gilead	
12h30	Parallel Sessions HIV Resistance	Parallel Sessions Free Oral Presentations (I)
14h00	Industry Satellite Symposium Janssen-Cilag Switching from stable regimen: which risks, which benefits ?	
15h30	Plenary Session Antiretroviral Strategies	
16h00	Coffee break sponsored by Gilead	
17h00	Keynote Lecture by Albert OSTERHAUS The Global Challenge of Emerging Infectious Diseases	
18h30	Industry Satellite Symposium Abbot Virology HIV, a chronic disease: what priorities to manage ?	

Friday 26 march 2010

8h30	Auditorium	Amphitheater Callelongue
10h30	Plenary Session Co-Infections	
11h00	Coffee break sponsored by Gilead	
12h30	Parallel Sessions HIV Controllers	Parallel Sessions Free Oral Presentations (II)
14h00	Parallel Sessions Long Term HIV Management (II)	Parallel Sessions Discussed Posters
15h00	Parallel Sessions Towards an HIV Vaccine	Parallel Sessions Post-CROI
15h30	Coffee break sponsored by Gilead	
16h30	Reporter Session	

9:30 ▶ 11:00

Plenary session / Session plénière

**EMERGING INFECTIOUS DISEASES /
MALADIES INFECTIEUSES EMERGENTES**

Auditorium

Chairpersons: Pierre Dellamonica (Nice, France), Gilles Hittinger (Toulon, France)

▶ **9:30**

Hepatitis E: State-of-the-Art / Hépatite E : Etat des Lieux

Harry Dalton, Royal Cornwall Hospital & Virus Reference Department, London, UK

▶ **10:00**

Lessons Learned from Chikungunya / Chikungunya : Leçons et Perspectives

Giovanni Rezza, Istituto Superiore di Sanità, Roma, Italy

▶ **10:30**

The Influenza Challenge / Le Défi Grippal

Tim Nguyen, Sylvie Briand *, World Health Organisation (WHO), Geneva



11:30 ▶ 13:00

Parallel session / Sessions parallèles

**LONG-TERM HIV MANAGEMENT (I) /
GESTION A LONG TERME DE L'INFECTION A VIH (I)**

Auditorium

Chairpersons: Isabelle Poizot-Martin (Marseille, France), Hervé Tissot-Dupont (Marseille, France)

▶ **11:30**

Ageing with HIV: Next Challenges / Vieillir avec le VIH : Défis à Venir

Martin Fisher, Brighton and Sussex University Hospital, NHS, Brighton, UK

▶ **12:00**

Cardiovascular Disease and HIV / Risque Cardiovasculaire et VIH

Esteban Martinez, Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain

▶ **12:15**

Ageing Metabolism and HIV / Vieillissement Métabolique et VIH

Jacqueline Capeau, INSERM, Paris, France

▶ **12:35**

Neurodegeneration in the HAART Era / Dégénérescence Neurologique à l'Époque des Trithérapies

Bruce Brew, University of New South Wales, Sydney, Australia

**PHARMACOLOGY OF HIV /
VIH, SESSION PHARMACOLOGIQUE**

Amphitheater Callelongue

Chairpersons: Rodolfe Garraffo (Nice, France), Caroline Solas (Marseille, France)

▶ **11:30**

Diffusion of New Antiretroviral Drugs in CSF / Diffusion des Nouveaux anti-Rétroviraux dans le LCR

Francesca Aweeka, University of California San Francisco, San Francisco, USA

► **11:50**

Inhibitory Quotient in HIV Pharmacology / Le Quotient Inhibiteur en Pharmacologie VIH

Charles La Porte, Ottawa Health Research Institute, Ottawa, Canada

► **12:10**

Drug-Drug Interactions - It is not only CYP450's which Matter / Interactions Pharmacologiques en dehors du Cytochrome * 450

David Back, University of Liverpool, Liverpool, UK

► **12:30**

Evidence-based TDM for Antiretroviral Drugs / Le Suivi Pharmacologique des ARV Fondé sur les Preuves

Caroline Solas, Hôpital de la Timone, Marseille, France

13:00 ► 14:00

**Industry Satellite Symposium /
Symposium Satellite de l'Industrie SCHERING PLOUGH**



**SHAPPING THE FUTURE OF CO-INFECTIONS WITH NOVEL AGENTS /
MODELER L'AVENIR DES CO-INFECTIONS A L'AIDE DE NOUVEAUX AGENTS**

Auditorium

Chairpersons: to be confirmed

► **Characteristics and Care of HIV-HCV coinfectd patients (Prospecth study 2009) / Profil et Prise en Charge du Patient Co-Infecté VIH-VHC en 2009 (Etude Prospecth 2009)**

Patrice Cacoub, Service de Médecine Interne, CHU Pitié Salpêtrière, Paris, France

► **Boceprevir: a trial in coinfectd patients / Boceprevir : un Protocole chez les Patients Coinfectés**

Stanislas Pol, Unité d'Hépatologie, Hôpital Cochin, Paris, France

Session COREVIH

Session in French only / Session en français uniquement

LE DEPISTAGE COMMUNAUTAIRE

Amphitheater Callelongue

Modérateurs : Isabelle Ravaux (Marseille, France), Chantal Vernay-Vaïsse (Lyon, France)

► **13:00**

Introduction sur le COREVIH

Isabelle Ravaux, PH en infectiologie, AP-HM, vice-présidente du Corevih Paca Ouest Corse

► **13:05**

Introduction sur le Dépistage Rapide

Chantal Vernay-Vaïsse, chef de service Prévention IST, Conseil Général des Bouches du Rhône

► **13:10**

Dépistage Rapide Auprès des Gays

Bruno Spire, chercheur en sociologie, Inserm U 912, président de AIDES : le projet ANRS «DRAG»

► **13:25**

Aspects Sociaux du Dépistage ou Expériences Européennes

Jean-Yves Le Talec, chercheur en sociologie, Université de Toulouse - Le Mirail, Toulouse, France

► **13:40**

Discussion avec la salle

14:00 ▶ 15:30

Plenary session / Session plénière

IMMUNOLOGY OF HIV / IMMUNOLOGIE DU VIH

Auditorium

Chairpersons: Giuseppe Tambussi (Milan, Italy), Jean-François Delfraissy (Paris, France)

▶ **14:00**

Is there a Role for Cytokine-Immune Based Therapy in HIV Disease Therapy? / Les Traitements Immunologique avec des Cytokine ont-ils une Place dans le VIH

Guido Poli, Istituto San Raffaele, Milan, Italy

▶ **14:30**

IL-2/IL-7 Therapies in HIV Infection. From CD4 Increases to Clinical Outcomes / Immunothérapie de l'infection par le VIH par IL-2 et IL-7

Yves Lévy, Hôpital Henri Mondor, Créteil, France

▶ **15:00**

NK Cells and Immune Activation in HIV / Cellules NK et Activation Immune dans l'Infection à VIH

Martin R. Goodier, Imperial College London, London, UK



Coffee break sponsored by Gilead / Pause café sponsorisée par Gilead



16:00 ▶ 17:00

Keynote lecture / Conférence plénière

Auditorium

25 Years after Discovering HIV as the Cause of AIDS: Prospects for a Vaccine / 25 Ans Après Avoir Découvert le VIH Comme Agent Causal du SIDA : Recherche d'un Vaccin

Robert Gallo, University of Maryland School of Medicine, Institute of Human Virology, Baltimore, USA

17:00 ▶ 18:30

Industry Satellite Symposium /
Symposium Satellite de l'Industrie MSD

STEERING FOR NEW STRATEGIES / METTRE LE CAP SUR DE NOUVELLES STRATÉGIES

Auditorium

Chairpersons: Alain Lafeuillade (Toulon, France), chairperson to be confirmed



La médecine fondée sur les preuves.

▶ **Can we Expect more than Undetectable Viremia Today? / Peut-on Attendre Plus que l'Indétectabilité Virologique Aujourd'hui**

Speaker to be confirmed

▶ **New Pharmacological Needs: Diffusion Outside the Blood Compartment? / Nouvelles Exigences Pharmacologiques : Diffusion Extra-Plasmatisque ?**

Rodolphe Garraffo, Hôpital Pasteur, Nice, France

▶ **First Line HAART: a Decisive Choice for the Long-Term / Première Ligne de Traitement : un Choix Décisif pour le Long Terme**

Speaker to be confirmed

8:30 ▶ 10:30

Plenary session / Session plénière

**HIV RESERVOIRS & PRIMARY INFECTION /
RESERVOIRS DU VIH ET PRIMO-INFECTION**

Auditorium

Chairpersons: Jacques Izopet (Toulouse, France), Alain Lafeuillade (Toulon, France)

▶ **8:30**

HIV Latency Explained to Clinicians / La Latence du VIH expliquée aux Cliniciens

Jose Alcamí, Instituto de Salud Carlos III, Madrid, Spain

▶ **9:00**

Update on HIV Reservoirs / Actualités sur les Réservoirs du VIH

Sarah Palmer, Swedish Institute for Infectious Disease Control and Karolinska Institute, Stockholm, Sweden

▶ **9:30**

Anti-HIV Latency Drugs / Traitements Anti-Latence

David Margolis, University of North Carolina, Chapel Hill, USA

▶ **10:00**

Translational Research at Acute HIV Infection / Recherche Translationnelle au Stade de Primo-infection

Jean-Pierre Routy, McGill University, Montreal, Canada



Coffee break sponsored by Gilead / Pause café sponsorisée par Gilead



GILEAD

11:00 ▶ 12:30

Parallel session / Sessions parallèles

HIV RESISTANCE / RESISTANCE DU VIH

Auditorium

Chairpersons: Catherine Tamalet (Marseille, France), Jean-Claude Tardy (Lyon, France)

▶ **11:00**

Use of New Technologies to Detect and Understand HIV Drug Resistance / Utilisation de Nouvelles Technologies pour Détecter et Comprendre les Résistances du VIH

Michael Kozal, Yale University, New Haven, USA

▶ **11:30**

Resistance to New Antiretrovirals (ETV, Anti-Integrases, Entry Inhibitors) / Résistance aux Nouveaux Anti-rétroviraux (Etravirine, anti-Intégrase, anti-CCR5)

Francesca Ceccherini-Silberstein, University of Rome Tor Vergata, Rome, Italy

▶ **12:00**

Use of New Drug Resistance Markers to Predict Virologic Response to Antiretrovirals / Utilisation de Nouveaux Marqueurs de Résistance pour Prédire la Réponse Virologique aux Anti-rétroviraux

Mark Wainberg, McGill University, Montreal, Canada



11:00 ► 12:30

FREE ORAL PRESENTATIONS I / PRESENTATIONS ORALES LIBRES I

Amphitheater Callelongue

Chairpersons: Patricia Enel (Marseille, France), Philippe Halfon (Marseille, France)

* indicates the presenting author / * indique le présentateur

► 11:00

0-01 Evolution of Tuberculosis/HIV Co-Infection in California During the Haart Era, 1996-2007
John Metcalfe (1) * Matt Facer (2) Mark Damesyn (2) Qiang Xia (2) James Watt (3) Julia Hill (3) Philip Hopewell (1) Janice Westenhause (3) Jennifer Flood (3)

(1) UCSF, San Francisco, United States of America(2) Office of AIDS, California Department of Public Health, San Francisco, United States(3) TB Control Unit, California Department of Public Health, Richmond, United States

► 11:10

0-02 Behavioral Features of Men Who Have Sex With Men (MSM) in China
Houlin Tang (1) Weidong Zhang (1) * Xinhua Sun (2) Fan Lv (1)

(1) Chinese Center for disease control and prevention, Beijing, China(2) Ministry of Health, Beijing, China

► 11:20

0-03 Screening of Differentially Expression Gene in HIV/HCV Coinfection Patients.
zhengrong Yang (1) * Jing Zhao (1) Lin Chen (1)

(1) Shenzhen Center for Disease Control and Prevention, Shenzhen, China

11:30

0-04 Nk-pDC Cross-Talk Leads to the Generation of Mtrail+Ifn-A+Cytotoxic pDC s Following HIV-1 Infection of pDC s. Consequences on the Control of Viral Replication
Héla Saïdi (1) Marlene Bras (1) * Formaglio Pauline (1) Melki Marie-thérèse (1) Gougeon Marie-Lise (1)

(1) Institut Pasteur, Paris, France

► 11:40

0-05 Th1/Th17 Gammadelta T Cells Are Expanded in HIV-1 Infected Patients and Respond to Candida Albicans.

Alessandro Poggi (1) * Daniela Fenoglio (2) Florinda Battaglia (2) Silvia Catellani (3) Alessandra Musso (1, 6) Maurizio Setti (4) Giuseppe Murdaca (5) Maria Raffaella Zocchi (6)

(1) National Institute for Cancer Research, , Genoa, Italy(2) CEBR, University of Genoa, Genoa, Italy(3) Department of Oncohematology, University of Genoa, Genoa, Italy(4) Department of Internal Medicine, University of Genoa, Genoa, Italy(5) Department of Semiotics, University of Genoa, Genoa, Italy(6) Scientific Institute San Raffaele, Department of Immunology, Milan, Italy

► 11:50

0-06 NK-Dependent Survival of HIV-1 Infected DCs. Pivotal Role of HMGB1.
Marie-Thérèse Melki (1) * Héla Saïdi (1) Marie-Lise Gougeon (1)

(1) Institut Pasteur, Paris, France

► 12:00

0-07 $\gamma\delta$ T Cells are ADCC Effectors in Elite HIV Controllers

Bhawna Poonia (1) David Riedel (1) Cristiana Cairo (1) Mohammed Sajadi (1) Cheryl Armstrong (1) David Pauza (1) *

(1) Institute of Human Virology, University of Maryland Medical School, Baltimore, United States of America

► 12:10

0-08 CpG Methylation Controls Reactivation of HIV from Latency

Jana Blazkova (1, 2, 3) * Katerina Trejbalova (1, 2) Francoise Gondois-Rey (1) Halfon Philippe (4) Philibert Patrick (5) Eric Verdin (6) Daniel Olive (1) Carine van Lint (3) Jiri Hejnar (2) Ivan Hirsch (1)

(1) INSERM, UMR891, Centre de Recherche en Cancérologie de Marseille and Institut Paoli-Calmettes, and Université Méditerranée, Marseille, France(2) Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic(3) Laboratory of Molecular Virology, Institute for Molecular Biology and Medicine (IBMM) University of Brussels (ULB), Gosselies, Belgium(4) Department of Virology, Alphabio Laboratory, Marseille, France(5) Department of Infectious Diseases, Hôpital Ambroise Paré, Marseille, France(6) Gladstone Institute of Virology and Immunology, San Francisco, United States

12:30 ▶ 14:00



Industry Satellite Symposium /

Symposium Satellite de l'Industrie TIBOTEC JANSSEN CILAG

SWITCHING FROM STABLE REGIMEN: WHICH RISKS, WHICH BENEFITS? / CHANGEMENT DE TRAITEMENT ANTIRÉTROVIRAL CHEZ LES PATIENTS EN SUCCES VIROLOGIQUE : QUELS RISQUES, QUELS BÉNÉFICES ?

Auditorium

Chairpersons: Isabelle Poizot-Martin (Hôpital Sainte Marguerite, Marseille, France), Jose Arribas (Hospital La Paz, Madrid, Spain)

▶ **NNRTI regimen: Capitalizing on the class? / Associations avec un NNRTI : changer en capitalisant sur la classe ?**

Mark Nelson, Chelsea and Westminster Hospital, London, UK

▶ **PI/r regimen: Without compromising the high genetic barrier? / Associations avec IP/r : changer sans compromettre la barrière génétique à la résistance ?**

Gianni di Perri, Department of Infectious Diseases, University of Torino, Torino, Italy

▶ **From 3 to 1: Is monotherapy a valid option for simplification? / De 3 vers 1 : la monothérapie est elle une option ?**

Christine Katlama, Service de Maladies Infectieuses et Tropicales, CHU Pitié Salpêtrière, Paris, France

14:00 ▶ 15:30

Plenary session / Session plénière

ANTIRETROVIRAL STRATEGIES / STRATEGIES ANTIRETROVIRALES

Auditorium

Chairpersons: Hans J Stellbrink (Hamburg, Germany), Alain Rieu (Toulon, France)

▶ **14:00**

ARV Strategies in 2010: What's New? / Stratégies de Traitement : Quoi de Neuf en 2010 ?

Jose Gatell, University of Barcelona, Barcelona, Spain

▶ **14:30**

ARV Therapy in Special Populations / Traitement Antirétroviral dans des Populations Particulières

Stéfano Vella, Istituto Superiore di Sanità, Rome, Italy

▶ **15:00**

Novel Targets, Novel Strategies / Nouvelles Cibles, Nouvelles Stratégies

Robert Redfield, Institute of Human Virology, Baltimore, USA



Coffee break sponsored by Gilead / Pause café sponsorisée par Gilead



16:00 ▶ 17:00

Keynote lecture / Conférence plénière

Auditorium

The Global Challenge of Emerging Infectious Diseases / Le Défi Mondial des Maladies Emergentes

Albert Osterhaus, Head Department of Virology, Erasmus MC, Rotterdam, The Netherlands

17:00 ► 18:30

Industry Satellite Symposium /
Symposium Satellite de l'Industrie ABBOTT

HIV, A CHRONIC DISEASE: WHAT PRIORITIES TO MANAGE? /
LE VIH, UNE PATHOLOGIE CHRONIQUE : QUELLES PRIORITÉS À PRENDRE EN CHARGE ?

Auditorium

Chairpersons: Alain Lafeuillade (Toulon, France), Christine Katlama (Paris, France)

► **HIV, Antiretrovirals and Central Nervous System / VIH, Antirétroviraux et Système Nerveux Central**
Scott Letendre, Division of Infectious Diseases, University of California San Diego, San Diego, USA

► **Management of Metabolic Disorders / La Gestion des Troubles Métaboliques**
Speaker to be confirmed

► **HIV Eradication, An Achievable Goal? / L'éradication, Un Objectif Atteignable ?**
Jean-Claude Tardy, Hôpital de la Croix Rouse, Lyon, France



8:30 ▶ 10:30

Plenary session / Session plénière

CO INFECTIONS / CO-INFECTIONS

Auditorium

Chairpersons: Marc Bourlière (Marseille, France), Isabelle Ravaux (Marseille, France)

▶ **8:30**

HIV / HPV Coinfection: State-of-the-Art / Co-infection VIH et HPV : Actualités

Franco Buonaguro, Laboratory of Molecular Biology and Viral Oncogenesis & AIDS Reference Center, Naples, Italy

▶ **9:00**

Hepatitis B: Treatment Strategies and Resistance / Hépatite B : Stratégies Thérapeutiques et Résistance

Vicente Soriano, Hospital Carlos III, Madrid, Spain

▶ **9:30**

New anti-HCV Drugs in the Pipeline / Les Nouvelles Molécules anti-VHC

Marc Bourlière, Fondation Saint Joseph, Marseille, France

▶ **10:00**

Liver Transplantation in Co-infected Patients / Transplantation Hépatique chez les Patients Co-infectés

Jose M Miró, Hospital Clínic, Barcelona, Spain



Coffee break sponsored by Gilead / Pause café sponsorisée par Gilead



GILEAD

11:00 ▶ 12:30

Parallel sessions / Sessions parallèles

HIV CONTROLLERS / PATIENTS VIH « NON PROGRESSEURS »

Auditorium

Chairpersons: Antoine Cheret (Toulon, France), Olivier Lambotte (Le Kremlin-Bicêtre, France)

▶ **11:00**

HIV Controllers: State-of-the-Art / Non Progresseurs : Etat des Lieux

Olivier Lambotte, INSERM U802, Université Paris-Sud, Le Kremlin-Bicêtre, France

▶ **11:30**

The Role of Cytotoxic T Cells / Rôle des Cellules T Cytotoxiques

Asier Sáez-Cirión, Unité de Régulation des Infections Rétrovirales, Institut Pasteur, Paris, France

▶ **11:50**

Potential Inflammatory Consequences in HIV Controllers / Conséquences Possibles de l'Inflammation chez les Non Progresseurs

Peter Hunt, Positive Health Program, San Francisco General Hospital, San Francisco, USA

▶ **12:10**

The Role of Host Genetic Determinants / Rôle des Facteurs Génétiques

Paul de Bakker, Brigham and Women's Hospital, Harvard Medical School-Partners Healthcare Systems Center for Genetics and Genomics, Boston, USA



11:00 ▶ 12:30

FREE ORAL PRESENTATIONS II / PRESENTATIONS ORALES LIBRES II

Amphitheater Callelongue

Chairpersons: Eric Jullian (Toulon, France), Patrick Phillibert (Marseille, France)

** indicates the presenting author / * indique le présentateur*

▶ **11:00**

0-09 Morbidity Associated with Hepatitis E Virus Infection in Endemic Setting.

Michael Favorov (1) * Makhmud Sharapov (2)

(1) International Vaccine Institute, Seoul, Korea, Republic of (2) Tashkent Pediatric Medical Institute and Central Asia Epidemiology Network, Ministry of Health, Tashkent, Uzbekistan

▶ **11:10**

0-10 Hepatic Cytolysis and Hepatitis E Virus Infection in HIV-Positive Patients.

Marie-Christine Mazon (1) Elisabeth Nicand (2) Sophie Tesse (2) Esma Badsì (3) Jean-Dominique Magnier (3) Marie-José Sanson Le Pors (1) Jean-François Bergmann (3) Pierre Sellier (3) *

(1) Hôpital Lariboisière, Service de bactériologie-Virologie, Paris, France (2) Hôpital d'Instruction des Armées du Val de Grâce, CNR virus de l'hépatite E, Paris, France (3) Hôpital Lariboisière, service de Médecine Interne, Paris, France

▶ **11:20**

0-11 Co-Receptor Usage Prediction at Quasispecies Level Using Ultra-Deep Pyrosequencing on both Circulating and Proviral HIV in Patients Candidates to CCR5 Antagonist Treatment

Isabella Abbate (1) * Gabriella Rozera (1) Chiara Tommasi (1) Alessandro Bruselles (1) Barbara Bartolini (1) Emanuele Nicastrì (1) Pasquale Narciso (1) Maria R. Capobianchi (1)

(1) INMI L. Spallanzani, Rome, Italy

▶ **11:30**

0-12 Semen May Harbor HIV Despite Effective HAART : Another Piece in the Puzzle

Philippe Halfon (1) * Claude Giorgetti (2) Hacène Khiri (1) Guillaume Pénaranda (1) * Terriou (2) G Porcu-Buisson (2) Véronique Chabert-Orsini (2)

(1) Laboratoire Alphabio, Marseille, France (2) Institut Médical de Reproduction, Marseille, France

▶ **11:40**

0-13 Tenofovir (TDF) Containing First-Line HAART is Associated with Changes in Plasma Parameters Suggestive of Increased Bone Resorption

Pablo Labarga (1) * Pablo Barreiro (1) Carlos A. Sanchez (1) Jose Medrano (1) Eugenia Vispo (1) Jose Vicente Fernandez (1) Francisco Blanco (1) Juan Gonzalez-Lahoz (1) Vicente Soriano (1)

(1) Hospital Carlos III, Madrid, Spain

▶ **11:50**

0-14 Side Effects Associated with Use of Nevirapine in HIV Treatment Naïve Patients with Respect to Baseline CD4 Count

Manoj Shevkani (1) * Bankim Mankad (1) Goral Rathod (1) Bipin Amin (1) Asha Shah (1) Umesh Nihalani (1) Hemang Purohit (1) Burzin Kavina (1) Urvi Derasari (1) Sanjeev Prajapati (1)

(1) ART center B J Medical College, Ahmedabad, India

▶ **12:00**

0-15 The Monet Trial: Correlation Between Hepatitis C Coinfection and HIV RNA Responses During Darunavir/Ritonavir Monotherapy, for Patients With HIV RNA <50 Copies/mL at Baseline.

Jose Arribas (1) * Maria Luisa Montes (1) Andrew Hill (2) Manyu Prakash (2) Christiane Moecklinghoff (2) MONET Study Group (3)

(1) Hospital la Paz, Madrid, Spain (2) Tibotec, Mechelen, Belgium (3) MONET Study Group, Europe, Spain

▶ **12:10**

0-16 Inhibitors of Human Immunodeficiency Virus-1 Replication Targeting the Human Dead-Box Polypeptide 3 (DDX3) RNA Helicase

Giovanni Maga (1) * Federico Falchi (2) Anna Garbelli (1) Marco Radi (2) Stefania Paolucci (3) Fausto Baldanti (3) Maurizio Botta (2)

(1) Institute of Molecular Genetics IGM-CNR, Pavia, Italy (2) Dept. of Technical Pharmacology, University of Siena, Siena, Italy (3) Virology Unit, University Hospital IRCCS S. Matteo, Pavia, Italy

12:30 ▶ 14:00

Parallel sessions / Sessions parallèles

LONG-TERM HIV MANAGEMENT (II) / GESTION A LONG TERME DE L'INFECTION A VIH (II)

Auditorium

Chairpersons: Isabelle Poizot-Martin(Marseille, France), Pierre Cau (Marseille, France)

with an unrestricted educational grant from Bristol-Myers Squibb /

Session organisée grâce à une subvention éducative sans condition de Bristol-Myers Squibb

▶ **12:30**

Progeria: a model for HIV? / La Progéria : un Modèle pour le VIH ?

Pierre Cau, Université de la Méditerranée Aix-Marseille II, Marseille, France

▶ **12:50**

Accelerated Immune Senescence in HIV / Vieillesse Immunologique Accélérée dans l'Infection VIH

Victor Appay, Hôpital Pitié-Salpêtrière, Paris, France

▶ **13:10**

Bone Aging and HIV / Vieillesse Osseux et VIH

Patrick Mallon, University College Dublin, Dublin, Ireland

▶ **13:20**

Sexual Dysfunction: HIV, HAART or premature aging? / Troubles Sexuels : VIH, traitement, ou vieillissement accéléré ?

Giovanni Guaraldi, University of Modena and Reggio Emilia, Modena, Italy

12:30 ▶ 14:00

DISCUSSED POSTERS / COMMUNICATIONS AFFICHEES DISCUTEES

Amphitheater Callelongue

Chairpersons: Mark Wainberg (Montreal, Canada), Jade Ghosn (Paris, France), Antoine Cheret (Toulon, France)

* indicates the presenting author / * indique le présentateur

▶ **12:30**

P-001 HIV/AIDS Infection in Ukraine: A Review of Epidemiological Data

Dr. Larissa Burruano (1) *

(1) CompNet, Clinic for Dermatology and Allergology, Ruhr-University, Bochum,, Germany

▶ **12:35**

P-002 Human Papillomavirus(HPV) Genotypes Among HIV-Infected and HIV-Uninfected Women in Mozambique

Massimo Magnano San Lio (1, 2) * Ivo Marchetti (3) Carla Carrilho (4) Maria Pia Cioni (3) Giovanni Guidotti (3, 1) Cristina Moscatelli (3, 1) Fabio Taponeco (6) Elias Suizane F. Walle (5) Ines Zimba (7) Generoso Bevilacqua (3)

(1) Community of Sant'Egidio, Drug Resources Enhancement against AIDS and Malnutrition (DREAM) Program, Roma, Italy(2) Azienda U.S.L. Roma F, Civitavecchia, Italy(3) Division of Surgical, Molecular and Ultrastructural Pathology, University of Pisa and University Hospital of Pisa, Pisa, Italy(4) Department of Pathology, Universidade Eduardo Mondlane, Hospital Central de Maputo, Ministério de Saúde, Maputo, Mozambique(5) Department of Gynecology, Hospital Central de Maputo, Ministério de Saúde, Maputo, Mozambique(6) Department of Gynecology, University Hospital of Pisa, Pisa, Italy(7) DREAM Health Center of Benfica, Maputo, Mozambique

▶ **12:40**

P-003 Factors Affecting Human Immunodeficiency Virus/ Acquired Immune Deficiency Syndrome Preventive Behavior among Pregnant Women in ANC Clinic in Maternity Hospital, Nepal

Sumi Amatya (1) *

(1) London School of Hygiene and Tropical Medicine, London, United Kingdom

▶ **12:45**

P-004 Treatment of Highly Pathogenic Filovirus Infections using Advanced Antisense Technology

Travis Warren (1) * Kelly Warfield (1, 3) Jay Wells (1) Dana Swenson (1, 3) Candace Lovejoy (2, 4) Patrick Iversen (2) Sina Bavari (1)

(1) USAMRIID, Ft. Detrick, Maryland, United States(2) AVI BioPharma, Inc., Corvallis, Oregon, United States(3) Integrated BioTherapeutics, Inc., Germantown, Maryland, United States(4) Siga Technologies, Inc., Corvallis, Oregon, United States

▶ **12:50**

P-005 The HIV-1 Viral Protein TAT Modulates Glutamate and GABA Exocytosis from Human and Mouse Neocortical Nerve Endings by Acting at Different Binding Sites

Maria Summa (1) Paolo Severi (1) Aldamaria Puliti (1) Maurizio Raiteri (1) Anna Pittaluga (1) *

(1) DIMES, Genova, Italy

▶ **12:55**

P-006 A Role for the Tetraspanin CD81 on the Late Steps of HIV-1 Replication in T-Lymphoblastic Cells

Delphine Muriaux (1) *

(1) Inserm U758, LYON, France

▶ **13:00**

P-007 Highjacking Of PI3K/AKT Signaling Pathway by Hepatitis C Virus in TLR9-Activated Human Plasmacytoid Dendritic Cells

Jonathan Florentin (1) * Clélia Dental (1) Gylène Firaguay (1) Françoise Gondois-Rey (1) Vassili Soumelis (2) Thomas F. Baumert (3) Jacques A. Nunès (1) Daniel Olive (1) Ivan Hirsch (1)

(1) INSERM, UMR891, Centre de Recherche en Cancérologie de Marseille and Institut Paoli-Calmettes, and Université Méditerranée, Marseille, France(2) Institut Curie, Paris, France(3) INSERM UMR_S748, Université de Strasbourg, Strasbourg, France

▶ **13:05**

P-008 Multicolor Flow Cytometry Analysis of Innate Responses Following in Vitro Interaction of PBMC with Hepatitis C Virus

Françoise Gondois-Rey (1) * Diana Herrera (1) Daniel Olive (1) Ivan Hirsch (1)

(1) INSERM, UMR891, Centre de Recherche en Cancérologie de Marseille and Institut Paoli-Calmettes, and Université Méditerranée, Marseille, France

▶ **13:10**

P-009 Comparison Of Cytotoxic Activity and Interferon-G Secretion by Natural Killer Cells in HIV-1 and HIV-2 Infected Individuals.

Samuel Victor Nuvoor (1) * Sarah Rowland-jones (2) Hilton Whittle (3) Assan Jaye (3)

(1) university of Cape Coast, Cape Coast, Ghana(2) wetherall Institute of Molecular Medicine, Oxford, United Kingdom(3) Medical Research Council, Banjul, Gambia

▶ **13:15**

P-010 Late HIV Infection Modulates the Expression and Activity of Cathepsin B, and its Inhibitors in Macrophages: Implications in Neuropathogenesis.

Eillen Rodriguez (1) * Marines Plaud (1) Rafael Romeu (2) Richard Skolasky (3) Loyda Melendez (1)

(1) University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico(2) University of Puerto Rico: Main Campus, San Juan, Puerto Rico(3) John Hopkins University, Baltimore, Maryland, United States of America

▶ **13:20**

P-011 Impact of Short Term HAART Initiated during the Acute or Chronic Stage on SIV Infection of the Male Genital Tract

Marina Moreau (1) * Anna Le Tortorec (1) Hélène Denis (1) Claire Deleage (1) Anne-Pascale Satie (1) Olivier Bourry (1) Pierre Roques (2) Bernard Jégou (1) Roger Le Grand (2) Nathalie Dejudcq-Rainsford (1)

(1) Inserm U625 GERHM, Rennes, France(2) Service d'immuno-virologie, CEA, Fontenay-aux-roses, France

▶ **13:25**

P-012 Enhanced Induction of HIV-Specific CTL by Dendritic Cell-Targeted Delivery of SOCS-1 siRNA

Sandesh Subramanya (1, 2) * Chunting Ye (1, 2) Sang-Soo Kim (1, 2) Premalata Shankar (1, 2)

(1) TTUHSC, El Paso, United States(2) Harvard Medical School, Boston, United States

▶ 13:30

P-013 Effect of Antiretroviral Therapy (ART) on HIV-1 & 2 (Subtype C) Infection and its Relationships to Cognitive Function and Quality of Life.

Gopukumar Kumarpillai (1) * Shobini L. Rao (1, 2) Prabha S.Chandra (1, 2) Satishchandra * (1, 2) Mahendra Kumar (1, 2, 3)

(1) University of Calgary, Calgary, Canada(2) NIMHANS, Bangalore, India(3) Miami School of Medicine, Florida, United States

▶ 13:35

P-014 Modulation of Tight Junction Expression by an MMP-9 Nanoplex: Implications for Maintaining Blood Brain Barrier Integrity in HIV-1 Encephalitis.

Supriya Mahajan (1) * Ravikumar Aalinkeel (1) Jessica Reynolds (1) Bindukumar Nair (1) Donald Sykes (1) Indrajit Roy (2) Adela Bonoiu (2) Elaine Lin (1) Paras Prasad (2) Stanley Schwartz (1)

(1) State University of New York at Buffalo, Buffalo, United States(2) Institute for Lasers, Photonics and Biophotonics, Buffalo, United States

▶ 13:40

P-015 Effect of Range of Spread of CD4 Count and RNA Level on the Efficacy of HIV Treatments

George Towfic (1) * Samira Kettoola (1)

(1) Clarke College, Dubuque, United States of America

▶ 13:45

P-016 HIV Infection in Elderly (Patients Aged more than 65 Years)

Farahnaz Almasi (1) *

(1) Paris 6 university, Paris, France

14:00 ▶ 15:00

Parallel sessions / Sessions parallèles

TOWARDS AN HIV VACCINE / MISE AU POINT D'UN VACCIN CONTRE LE VIH

Auditorium

Chairpersons: Alain Lafeuillade (Toulon, France), Pierre Pellegrino (London, UK)

▶ 14:00

New Pathways for Discovery / Nouvelles Voies de Recherche

To be confirmed

▶ 14:15

Recent Insights from Basic Science / Données Récentes des Sciences Fondamentales

Patrice Debré, INSERM U945, C.E.R.V.I., Paris, France

▶ 14:30

Progress towards development of an HIV Vaccine: A Report from the AIDS Vaccine Conference / Progrès vers la Mise au Point d'un Vaccin anti-VIH

Luigi Buonaguro, Molecular Biology and Viral Oncogenesis Unit & AIDS Reference Center, Istituto Nazionale Tumori «Fond. G. Pascale», Naples, Italy

▶ 14:45

What Can we Expect? / Que Peut-on Attendre ?

Giuseppe Pantaleo, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland



14:00 ▶ 15:00

POST CROI SESSION / SESSION « POST-CROI »

Amphitheater Callelongue

Chairpersons: Gérard Lepeu (Avignon, France), Jade Ghosn (Paris, France)

This session is dedicated to sum up the recent data presented at the 17th Conference on Retroviruses and Opportunistic Infection (CROI) held in San Francisco, USA on February 16-20, 2010. / Cette session a pour but de résumer les faits marquants de la dernière CROI organisée à San Francisco, USA, du 16 au 20 Février 2010.

▶ **14:00**

in Epidemiology / en Epidémiologie

Sabine Yerly, Hôpitaux Universitaires de Genève, Geneva, Switzerland

▶ **14:15**

in Virology / en Virologie

Leondios Kostrikis, University of Cyprus, Nicosia, Cyprus

▶ **14:30**

in Immunology / en Immunologie

Marie-Lise Gougeon, Institut Pasteur, Paris, France

▶ **14:45**

in Therapy / en Thérapeutique

Jade Ghosn, CHU Bicêtre, Paris, France



Coffee break sponsored by Gilead / Pause café sponsorisée par Gilead



GILEAD

15:30 ▶ 16:30

Reporter Session / L'Essentiel du Symposium

Auditorium

Chairpersons: Catherine Tamalet (Marseille, France), Alain Lafeuillade (Toulon, France)

▶ **15:30**

Virological Aspects / Aspects Virologiques

Jean-Claude Tardy, Hôpital de la Croix Rousse, Lyon, France

▶ **15:45**

Immunological Aspects / Aspects Immunologiques

Guido Poli, Istituto San Raffaele, Milan, Italy

▶ **16:00**

Clinical Aspects of HIV & Other Infections / Aspects Cliniques

Hans J Stellbrink, Infektionsmedizinisches Centrum Hamburg ICH, Hamburg, Germany

▶ **16:15**

Therapeutic Aspects of HIV & Other Infections / Aspects Thérapeutiques

Mark Nelson, Chelsea and Westminster Hospital, London, UK



* indicates the presenting author / * indique le présentateur

A Basic Science

► A1: HIV, Virology

P-017 Pro 2000, a Broadly Active Anti-HIV Sulfonated Compound, Inhibits Viral Entry by Multiple Mechanisms.

Dana Huskens (1) Albert T Profy (2) Kurt Vermeire (1) Dominique Schols (1) *

(1) Rega Institute for Medical Research, Leuven, Belgium(2) Indevus Pharmaceuticals, Lexington, United States

P-018 Potential Role of HIV-1 NEF and Human M6B in HIV-Associated Neurological Disorders

Jessica Moetter (1) * Silke Hoffmann (1) Esther Jonas (2) Dieter Willbold (1, 2)

(1) Forschungszentrum Juelich, ISB-3, Structural Biochemistry, Juelich, Germany(2) Heinrich-Heine-Universitaet Duesseldorf, Institut fuer Physikalische Biologie, Duesseldorf, Germany

P-019 CANCELLED

P-020 HIV-1 Evolution and Drug Resistance among Patients Receiving Antiretroviral Therapy in San Mateo County, California, 1997-2006.

Sudeb Dalai (1) * Jonathan Dyal (1) Keyan Salari (1) Seble Kassaye (1) Vivian Levy (2) Dennis Israelski (2) David Katzenstein (1)

(1) Stanford University School of Medicine, Stanford, United States(2) San Mateo Medical Center, San Mateo, United States

P-021 Length Variation in HIV-1 GP120 as the Product of DNA Misalignment Mechanism

Silvia Guglietta (1) Giuseppe Pantaleo (1) Cecilia Graziosi (1) *

(1) CHUV, Lausanne, Switzerland

► A2: HIV, Immunology

P-022 Nucleolin Relocalization Associated with Pre-Lethal Alterations of T Cell Morphology: Redefining Cell Death in HIV Infection.

Giuseppa Visalli (1) Maria Paola Bertuccio (1) Cristina Chirico (1) Giovanni Pellicanò (3) Pasquale Spataro (1) Riccardo Ientile (4) Isa Picerno (1) Giuseppe Piedimonte (2) *

(1) Department of Hygiene and Public Health University of Messina, Messina, Italy(2) Department of Biomorphology and Biotechnology University of Messina, Messina, Italy(3) Department of Human Patology University of Messina, Messina, Italy(4) Department of Biochemistry University of Messina, Messina, Italy

P-023 The Immunoglobulin Constant Region Modulates Antigen Binding Affinity and Functional Activities of the Broadly Neutralizing 2F5 HIV Specific Antibody

Daniela Tudor (1) * Anne-Sophie Drillet (1) Isabelle Schwartz-Cornil (2) Ruizhong Shen (3) Phillip D. Smith (3) Morgane Bomsel (1)

(1) Institut Cochin, Paris, France(2) INRA, Jouy-en-Josas, France(3) University of Birmingham, Alabama, United States of America

P-024 Definition of the Interacting Interfaces of Apobec3G and HIV-1 Vif using Mappit Mutagenesis Analysis

Delphine Lavens (1, 2) * Frank Peelman (1, 2) José Van der Heyden (1, 2) Isabel Uyttendaele (1, 2) Dominiek Catteeuw (1, 2) Bertrand Van Schouwbroeck (3) Julia Kurth (3) Sabine Hallenberger (3) Reginald Clayton (3) Jan Tavernier (1, 2)

(1) University of Ghent, Ghent, Belgium(2) VIB, Ghent, Belgium(3) TIBOTEC, Mechelen, Belgium

P-025 Expansion of Vdelta1 T Lymphocytes Reactive to C. Albicans in HIV-1 Infected Patients: Effect of Influenza Virus Vaccine.

Maria Raffaella Zocchi (1) * Daniela Fenoglio (2) Alessia Parodi (2) Alessandra Ferrera (2) Paolo Durando (3) Roberto Gasperini (3) Silvia Catellani (4) Alessandro Poggi (5)

(1) Scientific Institute San Raffaele, Department of Immunology, Milan, Italy(2) CEBR, University of Genoa, Genoa, Italy(3) Department of Health Science, San Martino Hospital, Genoa, Italy(4) Department of Oncohematology, Università di Genova, Genoa, Italy(5) National Institute for Cancer Research, Unit of Molecular Oncology and Angiogenesis, Genoa, Italy

P-026 HIV-Patients Discrimination According to Phenotype and Functional Assay of T-Cells Subsets.

Marie-Paule Guillaume (1) * Rafik Karmali (1) Francis Corazza (1) Jean Duchateau (1)

(1) CHU-Brugmann, Bruxelles, Belgium

P-027 Evaluation of Adult Immunological Outcomes from Kimironko Health Center Art Program, 2007 to 2008.

Andre Mbayiha H. (1) *

(1) AIDS Healthcare Foundation, Kigali, Rwanda

► **A3: Hepatitis, Virology**

P-028 Implications of HCV Natural Genetic Diversity on HCV NS5B Inhibitor NM283

Victoria L Demetriou (1) * Leondios G Kostrikis (1)

(1) University of Cyprus, Nicosia, Cyprus

P-029 Viral Variability Study in Follow-Up Sera from HIV-HBV-HCV Coinfected Patients

Stefania Taffon (1) Domenico Genovese (1, 2) Stefano Dettori (1) Paola Chionne (1) Claudio Argentini (1, 2) Maria Blasi (1) Stefania Catone (1, 2) Nicoletta Marino (3) Francesco Mazzotta (3) Maria Rapicetta (1) *

(1) Istituto Superiore di Sanita', Dept. MIPI, Viral Hepatitis Uni, Rome, Italy(2) Istituto Superiore di Sanita', Dept. FARM, Rome, Italy(3) Santa Maria Annunziata Hospital, Infectious Diseases Department, Florence, Italy

► **A4: Hepatitis, Immunology**

P-030 Pilot Trial of Oral Therapeutic HIV Vaccine, V-1 Immunitor, on HIV and HIV/HCV Patients in Russia

aldar bourinbaier (1) * vladimir orlovsky (1) vichai jirathitikal (1) orapun metadilogkul (1) popov dmitry (1, 1)

(1) immunitor USA Inc, college park, United States

P-031 Evaluation of Immune Response Profiles of Individuals With Chronic Hepatitis C Treated with Interferon Alpha and Ribavirin, in the Foundation of Tropical Medicine of Amazonas.

Ana Ruth Araújo (2) Liziara Silva Fraporti (1, 3) Kátia Luz Torres (1) João Paulo Diniz Pimentel (1) Tatiane Amabile (1) Andrea Tarragô (1) Laura Patrícia Viana Maia (1, 3) Nadja Garcia (1, 3) Walter Luiz Neves (1) Adriana Malheiro (1, 3) *

(1) Fundação de Hematologia e Hemoterapia do Amazonas, Manaus, Brazil(2) Fundação de Medicina Tropical do Amazonas, Manaus, Brazil(3) Universidade do Amazonas, Manaus, Brazil

► **A5: Others, Basic Science**

P-032 Child Care Centers are a Source of Comfort and Relief to HIV+ Mothers Accessing HIV Services - Taso Uganda Experience.

Moureen Kekirunga (1) * Rebecca Nvule (1) Josephine Birungi (1) Joy Nankabirwa (1) Francis Wasagaami (1)

(1) The AIDS Support Organisation, Kampala, Uganda



B Clinical Science

► B1: HIV, Clinical Manifestations

P-033 HIV-Related Morbidity Rate, Thirteen Years after the Introduction of Highly Active Antiretroviral Therapy (1996-2009)
Roberto Manfredi (1) *

(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy

P-034 The «AIDS Presenters» Phenomenon, Thirteen Years after the Availability of Potent, Combination Antiretroviral Therapy
Roberto Manfredi (1) *

(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy

P-035 The Prevalence and Presentation of Heart Disease in HIV Positive Adults Attending a Clinic at Mulago Hospital, Kampala, Uganda
Andrew Ocerro (1, 2) * Elly Katabira (2) Roy Mugerwa (2)

(1) Northern Uganda Malaria AIDS and Tuberculosis Programme, Gulu, Uganda(2) Makerere University, Kampala, Uganda

P-036 A 16-Year Prospective Survey of Mycobacterium Xenopi, Mycobacterium Kansasii and Mycobacterium Fortuitum Infection in Patients with HIV Disease
Roberto Manfredi (1) *

(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy

P-037 Vitamin D and HIV: Implications for Chronic Disease Management
Toby Dyner (1) * Virginia Cafaro (1) Valby Chow (1)

(1) SHARED PERSPECTIVES ON THERAPIES(SPOT), San Francisco, United States of America

P-038 Abstract Assessment of Knowledge, Attitude and Risk Practice for HIV Infection among Male Prisoners: The Case Maweni Prison, Tanga Region Tanzania
Joan Karomba (1) *

(1) Muhimbili National Hosp, Dar es saalam, Tanzania, United Republic of

P-039 Clinical and Immunological Presentation of New HIV-Infected Patients in an Outpatient Clinic
Edna Quintas (1) Sara Cardoso (1) * Carmela Pineiro (1) Danina Ferreira (1) Rosario Serrao (1) Jorge Soares (1) Rui Marques (1) Antonio Sarmento (1)

(1) Infectious Diseases. Hospital Sao Joao, Porto, Portugal

P-040 An HIV-Infected Patient with Associated, Lethal Rhinopharyngeal Actinomycosis and a Rapidly Progressing Local Adenocarcinoma
Roberto Manfredi (1) * Sergio Sabbatani (1) Ciro Fulgaro (1)

(1) Infectious Diseases, S. Orsola Hospital, Bologna, Italy

P-041 More than Ten Years without any Detectable HIV Viremia: Exceptionally Long-Term Non-Progressive HIV Infection
Roberto Manfredi (1) * Sergio Sabbatani (1) Giovanni Fasulo (1) Ciro Fulgaro (1)

(1) Infectious Diseases, S. Orsola Hospital, Bologna, Italy

► B2: HIV, Therapy

P-042 Antiretroviral Treatment and Expression of the mRNA Levels for PGP, MRP1, MRP4 and MRP5 in HIV Antiretroviral Naïve Patients. Follow-Up at 48 Weeks.

Francesca Falasca (1) Francesca Graziano (1) Laura Antonelli (2) Paola Maida (1) Claudia Montagna (1) Bambina Rizzo (1) Vincenzo Renda (2) Guido Antonelli (1) Ombretta Turriziani (1) *

(1) Department of Experimental Medicine, Virology Section, Sapienza University, Rome, Italy(2) Department of Infectious Diseases Umberto I Hospital, Rome, Italy

P-043 Clinical and Immunological Outcomes among Adult Patients Receiving Antiretroviral Therapy (ART) at an HIV/AIDS Program in Uganda

Simon Muhumuza (1) * Julius Ssempiira (1) Fred Semitala (1) Jennifer Namusoby (1) Joseph Ouma (1) Enid Mbabazi (1) Moses Kanya (1)

(1) Mulago-Mbarara Teaching Hospital's Joint AIDS Program (MJAP), Kampala, Uganda

P-044 Recombinant Soluble CCR5 and CXCR4 Chemokine Receptors as Anti-HIV Drug Targets

Victoria Kurbatska (1, 2) * Zhanna Rudevica (1, 2) Alexander Tsimanis (3) Ainars Leonciks (1, 2)

(1) Latvian Biomedical Research and Study center, Riga, Latvia(2) ASLA Biotech, Riga, Latvia(3) Bioactivity Ltd., Rehovot, Israel

P-045 Two Recent, Fixed Associations of Antiretroviral Nucleos(T)ide Analogues. A Prospective Assessment of their Therapeutic use in HIV Disease Management. A Field Study

Roberto Manfredi (1) *

(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy

P-046 Factors Associated with Non-Adherence to HAART in HIV-Positive Pregnant Women During Pregnancy, Peri- and Postpartum in Lima, Peru

Romina Tejada (1) * Jorge Alarcón (1) Carlos Velásquez (2) César Gutiérrez (1)

(1) Instituto de Medicina Tropical, UNMSM, Lima, Peru(2) Instituto Nacional Materno Perinatal, Lima, Peru

P-047 Treatment of HIV-2 Infection with Ritonavir/Lopinavir: Results at 60 Months. A Single-Center Study of 9 Patients

Philippe Genet (1) * Tahar Touahri (1) Laurence Courdavault (1) Frédérique Plassart (1) Juliette Gerbe (1)

(1) CH Victor Dupouy, Argenteuil, France

P-048 Efficacy and Tolerability of RAL, MVC and ETV Used in Combination in the Treatment of Highly Treatment Experienced HIV Infected Patients

Shilpa Sayana (1) Homayoon Khanlou (1) *

(1) AIDS Healthcare Foundation, Los Angeles, United States of America

P-049 Outcome of 1st Line Antiretroviral Therapy (ART) with Respect to Treatment Failure at Art Centre, B. J. Medical College, Civil Hospital, Ahmedabad

Bipin Amin (1) * Urvi Derasari (1) Umesh Nihalani (1) Hemang Purohit (1) Manoj Shevkani (1) Sanjeev Prajapati (1) Girish Prajapati (1) Bankim Mankad (1) Asha Shah (1) Burzin Kavina (1)

(1) ART center B J Medical College, Ahmedabad, India

P-050 Analysis of Protease Treatment-Associated Mutations in a Group of HIV-1 Subtype F Infected Individuals with Two Sequences Obtained in Different Time Points

Márcia Perez Resende Oliveros (1, 3) * Clarice Gameiro da Fonseca Pachi (2) Jorge Futoshi Yamamoto (2) Elizabeth Cavalieri (3) Maria Cecilia Araripe Sucupira (3) Luis Fernandez Lopez (1, 4) Ricardo Sobhie Diaz (3)

(1) School of Medicine, University of São Paulo – LIM 01 - HCFMUSP, Sao Paulo, Brazil(2) ANSP- Academic Network of São Paulo, Sao Paulo, Brazil(3) Federal University of São Paulo – Retrovirology Laboratory, Sao Paulo, Brazil(4) CIARA – [Center for Internet Augmented Research and Assessment] – Florida International University, Miami, United States of America

P-051 Efficacy and Safety of TDF+FTC+EFV in Naïve Patients Initiating HAART; an Observational Study Comparing Atripla vs Truvada/Sustiva Exposure.

Carlos Alberto Sanchez (1) * Jose Medrano (1) Pablo Labarga (1) Eugenia Vispo (1) Aida Calviño (1) Luz Martín-Carbonero (1) Pablo Barreiro (1) Vicente Soriano (1)

(1) Hospital Carlos III, Madrid, Spain

P-052 Fusion Inhibitors and their Evolving Role During Salvage Antiretroviral Therapy. Seven Years of Experience with Enfuvirtide

Roberto Manfredi (1) *

(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy

P-053 Our Experience in 2nd Line Anti Retroviral Therapy (ART) at State AIDS Clinical Expert Panel (SACEP) Clinic, Centre of Excellence (CoE), Art Centre, B. J. Medical College, Civil Hospital, Ahmedabad

Bankim Mankad (1) * Hemang Purohit (1) Asha Shah (1) Manoj Shevkani (1) Burzin Kavina (1) Bipin Amin (1) Umesh Nihalani (1) Sanjeev Prajapati (1) Urvi Derasari (1) Girish Prajapati (1)

(1) ART center B J Medical College, Ahmedabad, India

P-054 Treatment Outcomes in Patients Receiving Combination Antiretroviral Therapy

Kenneth Agu (1) * Uche Ochei (1) Azuka Oparah (1) Obialunamma Onoh (2)

(1) Department of Clinical Pharmacy and Pharmacy Practice, University of Benin, Benin, Nigeria(2) West African Postgraduate College of Pharmacists, Lagos, Nigeria

P-055 Lopinavir/R + Efavirenz Combination as a Potent NRTI Sparing Antiretroviral Therapy.

Philippe Henrivaux (1) * Yvette Fairon (2) Benoît Kabamba (3) Jean-Cyr Yombi (4) Patrick Goubau (3) Bernard Vandercam (4)

(1) CHC Clinique St Joseph, Médecine Interne, Liège, Belgium(2) ASBL, Liège, Belgium(3) Laboratoire de Référence SIDA, Cliniques Universitaires Saint Luc, Brussels, Belgium(4) Centre de Référence SIDA, Cliniques Universitaires Saint Luc, Brussels, Belgium

P-056 Experience with Art Adherence Counseling at Muhimbili National Hospital, Dar Es Salaam, Tanzania

Joan Karomba (1) *

(1) Muhimbili National Hosp, Dar Es Salaam, Tanzania, United Republic Of

P-057 Interventions to Promote Adherence to Antiretroviral Therapy (HAART) among Adult Patients at an HIV/AIDS Program in Uganda:

Simon Muhumuza (1) * Violet Gwokyalya (1) Elizabeth Kutamba (1)

(1) Mulago-Mbarara Teaching Hospitals' Joint AIDS Program (MJAP), Kampala, Uganda

P-058 Lowering HIV Fitness and Replication Rate by Administration of Lamivudine Alone, in Extensively Resistant HIV-Infected Patients, as a «Bridging» Strategy Towards Optimized Salvage Regimens

Roberto Manfredi (1) *

(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy

P-059 Impact of Maraviroc on Immune Restoration in an Advanced Stage HIV-Infected Patient

Sylvie Bregigeon (1) Amélie Menard (1) Olivia Faucher (1) Catherine Tamalet (2) Caroline Solas (3) Véronique Obry-Roguet (1) Isabelle Poizot-Martin (1) *

(1) Department of Immuno-hematology, HIV-Clinical center; Hospital SainteMarguerite, Marseilles, France(2) Fédération de Microbiologie Clinique, Hôpital de la Timone, Marseilles, France(3) Laboratoire de Pharmacocinétique et de Toxicologie, Hôpital de La Timone, Marseilles, France

P-060 «Self-Managed», Inadequate «Adherence» to Antiretroviral Therapy, Limited to one Half of Standard Dosages, Followed by an Unexpected, Sustained Virological and Immunological Success
Roberto Manfredi (1) *

(1) *Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy*

P-061 Without a Quality Management Tool, All HIV Managers Shall not Realise any Steps Forward for Improvement. A Taso Uganda Experience.

Denis Mpiima (1) * Ceasar Luzze (1) Nicholas Kizito (1, 1)

(1) *The AIDS Support Organisation, Kampala, Uganda*

► **B3: HIV, Side Effects**

P-062 Cystatin C and Cardiovascular Risk in HIV Infected Patients

Katia Falasca (1) Claudio Ucciferri (1) * Paola Mancino (1) Francesca Vignale (1) Jacopo Vecchiet (1)

(1) *Infectious Disease Clinic, Department of Medicine and Science of Aging, G. d'Annunzio University, Chieti, Italy*

P-063 Effects on Insulin Sensitivity and Hepatic Safety of Atazanavir in HCV/HIV Coinfected Patients versus HIV Monoinfected. A Prosective 48-Week Study.

Héctor Mejjide (1) Álvaro Mena (1) * Ángeles Castro (1, 2) Pilar Vázquez (1) Soledad López (1) Joaquín Serrano (1) Laura Bello (1) José Pedreira (1)

(1) *HIV Unit, Internal Medicine Service. University Hospital of A Coruña, A Coruña, Spain*(2) *University of A Coruña, A Coruña, Spain*

P-064 Hypertension and Microalbuminuria in HIV Infected Patients: Beneficial Effects of the Treatment with Telmisartan

Claudio Ucciferri (1) * Paola Mancino (1) Katia Falasca (1) Francesca Vignale (1) Jacopo Vecchiet (1)

(1) *Infectious Disease Clinic, Department of Medicine and Science of Aging, "G. d'Annunzio" University, Chieti, Italy*

P-065 NRTIS (ZDV and D4T) Side Effects in PLHAS Attending the Antiretroviral Treatment Centre of B. J. Medical College and Civil Hospital at Ahmedabad, Gujarat, India

Umesh Nihalani (1) * Asha Shah (1) Burzin Kavina (1) Bipin Amin (1) Urvi Derasari (1) Hemang Purohit (1) Bankim Mankad (1) Sanjeev Prajapati (1) Girish Prajapati (1) Manoj Shevkani (1)

(1) *ART center B J Medical College, Ahmedabad, India*

P-066 Depression and Self-Esteem of Patients Positive for HIV / AIDS in an Inland City of Brazil

Carolina Castrighini (1) Elucir Gir (1) * Lis Neves (1) Renata Reis (2) Marli Galvão (3) Myeko Hayashido (1)

(1) *São Paulo University - School Of Nursing Ribeirão Preto, Ribeirão Preto, Brazil*(2) *Alagoas Federal University, Maceió, Brazil*(3) *Ceará Federal University, Fortaleza, Brazil*

P-067 A Young Patient with Perinatal HIV Infection Treated for 17 Consecutive Years with Antiretroviral Therapy: Extremely Severe Lipo-Accumulation Picture

Roberto Manfredi (1) *

(1) *Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy*

P-068 Emerging HIV-Associated Concerns: Osteopenia and Osteoporosis. Easy Prevention and Management Guidelines

Roberto Manfredi (1) *

(1) *Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy*

P-069 Interactive Theatre for HIV/AIDS Side Effects on Youth Sexuality Reproductive Health and Rights in Pakistan to Learn and Practice

Sana Sohail (1) *

(1) Chanan Development Association (CDA), Lahore, Pakistan

► **B4: HIV, Tumors**

P-070 Interplay Between HIV and Micrnas in AIDS-Related Lymphomas

Giulia De Falco (1) * Anna Luzzi (1) Federica Morettini (1) Anna Onnis (1) Lorenzo Leoncini (1)

(1) Dept. Human Pathology & Oncology, University of Siena, Siena, Italy

P-071 Non-AIDS Related Malignancies 13 Years after the Availability of Combined Antiretroviral Therapy

Roberto Manfredi (1) *

(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy

► **B5: HIV, Others**

P-072 Prolonged Elevation of Viral Loads in HIV-1-Infected Children in a Region of Intense Malaria Transmission in Northern Uganda

Herbert Kiyingi (1, 2) * Thomas Egwang (1) Maria Nannyonga (2)

(1) medbiotech Laboratories, Kampala, Uganda(2) Nsambya Hospital, Kampala, Uganda

P-073 Women HIV Education, Capacity Building and Economic Empowerment Initiative

Caroline Agochukwu (1) *

(1) Health Matters Incorporated, Lagos, Nigeria

P-074 Tuberculosis with Pulmonary Involvement in HIV Patients

Lígia Fernandes (1) * Nuno Marques (2) Ana Lebre (2) Joaquim Oliveira (2) José Saraiva da Cunha (2) António Meloço Silvestre (2)

(1) Serviço de Pneumologia, Centro Hospitalar de Coimbra, Coimbra, Portugal(2) Departamento de Doenças Infecciosas, Hospitais da Universidade de Coimbra, Coimbra, Portugal

P-075 Service Outcome of Antiretroviral Post-Exposure Prophylaxis (PEP) for Occupational HIV Exposure among Health Care Personnel

Asha Shah (1) * burzin kavina (1) sanjeev prajapati (1) hemang purohit (1) manoj shevkani (1) urvi derasari (1) umesh nihalani (1) bipin amin (1) bankim mankad (1) girish Prajapati (1)

(1) ART center B J Medical College, Ahmedabad, India

P-076 Glomerular Filtration (GF) Determined by Creatinine Clearance (CCR) in 24 Hours Urine and Cockcroft & Gault (CG) and Modification of Diet in Renal Disease (MDRD) Equations in a Large Cohort of HIV+ Patients

Pablo Labarga (1) * Marta Albalade (2) Pablo Barreiro (1) Elena Alvarez (1) Luz Martín-Carbonero (1) Javier Pinilla (3) Eugenia Vispo (1) Jose Medrano (1) Carlos A Sanchez (1) Vicente Soriano (1)

(1) Hospital Carlos III, Madrid, Spain(2) Hospital Infanta Leonor, Madrid, Spain(3) Hospital San Pedro, Logroño, Spain

P-077 Factors Associated with Development of Opportunistic Infections among Patients on Art at a Ugandan Program-MJAP

Simon Muhumuza (1) * Joseph Ouma (1) Fred Semitala (1)

(1) Mulago-Mbarara Teaching Hospitals Joint AIDS Program (MJAP), Kampala, Uganda

P-078 Evaluation of the Therapeutic Educational Consultations of Patients Infected by the Human Immunodeficiency Virus (HIV)

Jennifer Grangé (1) Frederique Plassart (1) *

(1) Charles Foix Hospital, Ivry sur seine, France

P-079 An Episode of Serious CMV Colitis in a HIV Patient with an Optimal Viro-Immunological Response and who Resulted Negative to Sierological Research of CMV.

Silvia Costarelli (1) * Silvia Garilli (1) Angelo Pan (1) Giuseppe Carnevale (1)

(1) Cremona Hospital, Cremona, Italy

P-080 Immune Response Characterization in HIV/HCV Co-Infected Patients of Medicine Tropical Foundation

Adriana Malheiro (1, 3) * Liziara Silva Fraporti (1, 3) Flamir Victoria (2) Kátia Luz Torres (1) João Paulo Diniz Pimentel (1) Andrea Tarragô (1) Laura Patricia Viana Maia (1, 3) Felicien Vásquez (1) José Eduardo Levi (4) Marilu Victoria (2)

(1) Fundação de Hematologia e Hemoterapia do Amazonas, Manaus, Brazil(2) Fundação de Medicina Tropical do Amazonas, Manaus, Brazil(3) Universidade Federal do Amazonas, Manaus, Brazil(4) Universidade Estadual de São Paulo, São Paulo, Brazil

P-081 Advocacy and Piloting the First Needle and Syringe Exchange Program in Iranian Prisons

Mohammad Shahbazi (1) * Marziyeh Farnia (1) Mohammadreza Keramati (1) Ramin Alasvand (1)

(1) Iran Prisons Organization, Tehran, Iran, Islamic Republic of

P-082 Small Intestine Enteroscopy: A New Diagnostic Tool not only in HIV Infection

Christian Traeder (1) * Julia Breitzkreutz (1) Keikawus Arastéh (1)

(1) Vivantes Auguste Viktoria Hospital, Berlin, Germany

► **B6: Hepatitis, Therapy**

P-083 Chronic HCV Treatment with Peginterferon-Ribavirin and Severe Tuberculosis Re-Activation

Roberto Manfredi (1) * Leonardo Calza (1)

(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy

P-084 Severe Psoriasis Emerged after Treatment of Chronic HCV Co-Infection with Pegylated-Nterferon and Ribavirin, Supported by Neutropenia Rescue with Repeated Filgrastim Administration

Roberto Manfredi (1) * Sergio Sabbatani (1)

(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy

► **B7: Hepatitis, Other**

P-085 The Experience of Pain Among Patients Living with Hepatitis C: an Assessment of Prevalence and Needs

Christine Cabrera (1) * Kimberly Corace (2) Louise Balfour (2) George Tasca (2) Curtis Cooper (2) Jonathan Angel (2) William Cameron (2) Paul MacPherson (2) Gary Garber (2)

(1) University of Ottawa, Ottawa, Canada(2) The Ottawa Hospital-General Campus, Ottawa, Canada

P-086 Spontaneous HCV Clearance in a Patient with HIV Infection and a Concurrent, Never Treated, Evolutive HCV Hepatitis, after over Twenty Years of Chronic Co-Infection

Roberto Manfredi (1) * Nicola Dentale (1) Leonardo Calza (1)

(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy

P-087 Preventive Behavior among Doctors with Respect to Hepatitis-B in Bolan Medical Complex Hospital, Quetta, Pakistan
Khalid Rehman (1) *

(1) Health, Quetta, Pakistan

► B8: STDs

P-088 Seroepidemiology of Infection with Herpes Simplex Virus Type 2 (Hsv2) among Asymptomatic Students Attending Islamic Azad University of Kazeroun, Southwest of Iran.
Daryoush Tayyebi (1) * Mojgan Tabatabaee (1) Marjan Rahsaz (2)

(1) Islamic Azad University-Kazeroun Branch, Kazeroun, Iran, Islamic Republic Of(2) Transplantation Research Center, Shiraz, Iran, Islamic Republic Of

P-089 Integrating STI Screening Tool Improves STI Screening and Diagnosis in HIV Patients
Stephen Okoboi (1) * Moses Moses (1) Daniel Bogere (1)

(1) The AIDS Support Organization , Tororo, Uganda

► B9: Other, Clinical Science

P-090 Disturbance of HDL Apolipoprotein AI Metabolism in Severe Hyperlipidemic and Lipodystrophic HIV Patients on a Protease Inhibitor Treatment.
Khadija Ouguerram (1) * Yassine Zair (1) Stéphanie Billon (1) Michel krempf (1)

(1) INSERM U915, Nantes, France

P-091 Pulmonary and Disseminated Tubercular Disease by Bacillus of Calmette-Guérin after Administration as a Local Adjuvant Immunotherapy of Relapsing Bladder Adenocarcinoma
Roberto Manfredi (1) * Nicola Dentale (1)

(1) Infectious Diseases, S. Orsola Hospital, Bologna, Italy

P-092 Educational Intervention and HIV Infection: Preliminary Results.

Sylvie Bregigeon (1) * Brigitte Canet (1) Véronique Obry-Roguet (1) Amélie Menard (1) Isabelle Poizot-Martin (1)

(1) 1department Of Immuno-Hematology, Hiv-Clinical Center, Hospital Saintemarguerite, Marseilles, France

P-093 Incidence Rate of Nosocomial Urinary Tract Infections in Intensive Care Unit Patients of Zanjan's Shafeeieh Hospital
Vida Sadeghzadeh (1) *

(1) Azad University ,Zanjan Branch , Zanjan, Iran, Islamic Republic Of

P-094 Hospital Based Palliative Care Approach TO HIV/AIDS- A Nigeria Experience
Folaju Olusegun Oyebola (1) *

(1) Pain And Palliative Medicine Department. Federal Medical Centre Idi-Aba. P.M.B 3031, Sapon P.O., Abeokuta, Nigeria



C Epidemiology & Prevention

► C1: HIV, Epidemiology & Prevention

P-095 Destruction HIV Viral RNA by SiDNA Triggering RNase H

Karin Moelling (1) *

(1) University , Zurich, Switzerland

P-096 A Research Report on «Positive Prevention» Intervention in Two Ethnic Habitats along the Border with Myanmar in Yunnan

Yan Guo (1) F Bin Su (1) *

(1) Yunnan Daytop Drug Abuse Treatment and Rehabilitation Center, Kunming, China

P-097 Results from a Multimedia Testing and Counseling Program in an Urban Emergency Department

Yvette Calderon (1, 2) * Ethan Cowan (1, 2) Jade Fettig (1) Karachi Egbuta (1) Jason Leider (1, 2)

(1) Jacobi Medical Center, New York, United States(2) Albert Einstein College of Medicine, New York, United States

P-098 Recent HIV Infection among Newly Diagnosed with HIV Cases in Turin, Italy

Mariangela Raimondo (1) * Chiara Pasqualini (2) Valeria Ghisetti (3) Vincenza Regine (1) Laura Camoni (1) Maria Cristina Salfa (1) Barbara Suligo (1)

(1) Istituto Superiore di Sanità, Rome, Italy(2) SEREMI ASL 20, Alessandria, Italy(3) Amedeo di Savoia Hospital, Turin, Italy

P-099 HIV/AIDS Epidemic Features and Trends in Setif City (Algeria) From 1986 to 2009

Amel Ouyahia (1) * Mounira Rais (1) Abdelkader Gasmi (1) Wahiba Guenifi (1) Salah Mechakra (1) Abdemadjid Lacheheb (1)

(1) faculte de medecine centre hospitalo universitaire , setif, Algeria

P-100 HIV-Related Risk Factors among Male Sex Workers in Different Settings in Shenzhen, China

Jin Zhao (1, 2) * Wen-De Cai (2) Lin Chen (2) Yong-Xia Gan (2) Yun-Yun Zi (2) Jin-Quan Cheng (2) Xiao-Rong Wang (1) Ming-Liang He (1)

(1) School of Public Health of Primary Care, The Chinese University of Hong Kong, Hong Kong , Hong Kong(2) Shenzhen Center for Disease Control and Prevention, Shenzhen, China

P-101 The Trend of HIV/AIDS Prevalence among IDU's in Iranian Prisoners (1376-1386)

Mohammad Shahbazi (1) * Marziyeh Farnia (1) Ghobad Moradi (1) Bahman Ebrahimi (1)

(1) GFATM(theglobalfund.org) - Iran Prisons Organization, Tehran, Iran, Islamic Republic of

P-102 HIV Infection Newly Diagnosed in Northern Italy. Evolving Trends

Roberto Manfredi (1) *

(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy

P-103 Men who Have Sex with Men(MSM) and HIV Epidemic in China: A Web-Based Study on MSM

Jianmin Xing (1) Konglai Zhang (2) *

(1) Beijing University of Chinese Medicine, Beijing, China(2) Peking Union Medical College, Beijing, China

P-104 The Effects of Multiple Types of Child Maltreatment and Subsequent HIV Risk Behaviors among Young Women

Hyeouk Chris Hahm (1) * Elizabeth Porter (1) Lisa Ng (1)

(1) Boston University, Boston, United States of America

P-105 Killer Immunoglobulin-Like Receptor Genes and Heterosexual HIV-1 Transmission

Aimee Merino (1) * Rakhi Malhotra (1) Matt Morton (1) Joseph Mulenga (2, 3) Susan Allen (2, 3) Eric Hunter (3) Jianming Tang (1) Richard Kaslow (1)

(1) UAB, Birmingham, United States of America(2) Rwanda-Zambia HIV Research Group, Lusaka, Zambia(3) Emory, Atlanta, United States of America

P-106 Non-Injected Illicit Drugs and Alcohol and HIV-Related High-Risk Sexual Behaviors in a Street-Recruited Sample of Non-Injecting Drug Users in New York City

Ashutosh Mishra (1) * Daniel Pilowsky (1) Judith Jacobson (1)

(1) Columbia University, New York, United States of America

P-107 A Validated Stigma Scale Measures Decreased HIV-Related Stigma Among Men in a Community-Based HIV Prevention Services Program in Rural Maharashtra, India.

Ashok Dyalchand (1) *

(1) Institute of Health Management, Pachod, Pune, India

P-108 Difficulties of Routine Rapid HIV Screening in Emergency Department

Philippe Genet (1) * Catherine Legall (1) Pascal Peudepiece (1) François Briand (1) Laurence Courdavault (1)

(1) CH Victor Dupouy, Argenteuil, France

P-109 Familial Factors and Prenatal HIV Care Adherence among HIV Positive Pregnant Women in Birmingham, Alabama, USA

Ekta Saroha (1) * Faith Fletcher (2) Mirjam-Colette Kempf (1) Marsha Sturdevant (1)

(1) University of Alabama at Birmingham, Birmingham, United States(2) University of South Carolina, Columbia, United States

P-110 Subacute and Rehabilitation Care Facilities « Soins de Suite et De Réadaptation (SSR) », Dedicated to HIV Patients in Marseilles, France

Jean-Paul Dimet (1) Gabrielle Vinai (1) Berengère Labarrière (1) Loïc Julien (1) Eliane Lerda (1) Nadia Timezougat (1) Nathalie Petit (1) *

(1) Polyclinique La Feuilleraie, Marseille, France

P-111 Identifying Practices and Strategies to Increase HIV Testing among Haitian Migrant Communities

Jonathan Santiago (1, 2) *

(1) Agence de la santé et des services sociaux de Montréal, Montréal, Canada(2) University of Washington School of Public Health, Seattle, United States

P-112 HIV/AIDS Epidemic in Belarus

Vladimir Eremin (1) * Elena Gasich (1) Sergei Eremin (1) Ekaterina Ambarcumian (1) Vladimir Lukashov (3)

(1) Research Institute for Epidemiology & Microbiology, Minsk, Belarus(2) D.I. Ivanovsky Institute of Virology, Moscow, Russian Federation(3) Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

P-113 Cervical Dysplasia in Postmenopausal Patients Infected by HIV.

Pierre-François Ceccaldi (1, 2) * Claudia Ferreira (1) Florence Coussy (1) Charlotte Mechler (1) Catherine Crenn-Hebert (1) Laurent Mandelbrot (1)

(1) AP-HP Louis Mourier, Colombes, France(2) AP-HP Beaujon, Clichy, France

P-114 Reaching Boys in Saunas

Carol Emerson (1) *

(1) Royal Victoria Hospital, Belfast, United Kingdom



P-115 Knowledges, Attitudes and Practices in University Students about Sexual and Reproductive Health and HIV/AIDS in Bogotá D.C., Colombia

Oscar David Diaz-Sotelo (1) *

(1) Universitat Autònoma de Barcelona, Barcelona, Spain(2) RANDOM Foundation, Bogotá D.C., Colombia

P-116 Transition to Adult Clinics in Youth Living with HIV since Birth

Mylène Fernet (1) * Marie-Eve Richard (1) Joseph Josy Lévy (1) Joanne Otis (1) Lapointe Normand (2) Samson Johanne (2) Guylaine Morin (2) Kimberly Wong (1) Jocelyne Thériault (1) Germain Trottier (3)

(1) Université du Québec à Montréal, Montréal, Canada(2) CHU Ste-Justine, Université de Montréal, Montréal, Canada(3) Université Laval, Québec, Canada

P-117 Knowledge and Attitudes on HIV/AIDS and Sexual Behaviour among Male Soldiers in Sri Lanka Army

Saveen Semage (1) * Sujatha Samarakoon (2)

(1) Sri Lanka Army Medical Services, Colombo, Sri Lanka(2) National STD/AIDS Control Program, Ministry of Healthcare & Nutrition Sri Lanka, Colombo, Sri Lanka

P-118 Female Condom in HIV/AIDS Prention among Female Commercial Sex Workers in Nigeria: A Geographical Perspective

Emmanuella Onyenechere (1) *

(1) Imo State University, Dwerri, Nigeria

P-119 Human Immunodeficiency Virus Viral Markers Seroperevalence in First-Time Healthy Blood Donors Referred to Transfusion Centers of Bushehr Province, South of Iran (April2004 to March2008)

Hesam_oddin Maneshi (1) * Mojtaba Karimi (2) Shahab Zare (1) Gholam Reza Hajiani (2)

(1) Bushehr University of Medical Sciences - Student's Research Committee, Bushehr, Iran, Islamic Republic of(2) Bushehr Blood transfusion organization, Bushehr, Iran, Islamic Republic of

P-120 Correlates of HIV Knowledge and Sexual Risk Behaviors among Female Military Personnel

Ekere Essien (1) * Osaro Mgbere (1, 2) Ernest Ekong (1, 3) Susan Abughosh (1) Emmanuel Monjok (1)

(1) University of Houston, Houston, United States(2) Houston Department of Health and Human Services, Houston, United States of America(3) Institute for Health Research and Development, Lagos, Nigeria

P-121 Ethnological Inquiry into Sexual Behaviours at Risk to Homosexuals in Portugal

Marta Maia (1) * Khalid Fekhari (2)

(1) CRIA - ISCTE, Lisbon, Portugal(2) Instituto Piaget, Viseu, Portugal

P-122 Stigma and HIV Risk Behaviors of Transgender Women in Nepal: Implications for HIV Prevention

Erin Wilson (1) * Sunil Babu Pant (2)

(1) Center for AIDS Prevention Studies, San Francisco, United States(2) Blue Diamond Society, Kathmandu, Nepal

P-123 Seroprevalence of Hepatitis B- Surface Antigen among Non-Professional Blood Donors in Selected Hospital in Dhaka City.

Rezaul Karim (1) *

(1) NIPSOM, DHAKA, Bangladesh

P-124 HIV Prevalence Among TB Patients Attending Dots Centres in Rural Haryana, India

Ravi Kumar Balu (1) * Sanjay Rai (1) Shashi Kant (1) Krishnan Anand (1) Lalit Dar (1) Urvashi Singh (1)

(1) All India Institute of Medical Sciences, New Delhi, India

P-125 Factor Associated with Getting HIV Tested for Infant whose Born from HIV Infected Mothers, Thailand : 2008

Pradabporn Duangajna (1) *

(1) Office of Disease Prevention and Control Region 3 Chonburi Thailand, Chonburi, Thailand

P-126 Condom Use and Sexual Partnerships among Truck Drivers in Southern Brazil

Daniela Knauth (1) Andréa Fachel Leal (1) Flavia Pilecco (1) *

(1) UFRGS, Porto Alegre, Brazil

P-127 CANCELLED

P-128 HIV Infection and the Immigration in Italy. Consequences on Inpatient Hospitalizations and Day-Hospital Admissions at a Metropolitan Hospital, during the Last Nine Years

Roberto Manfredi (1) *

(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy

P-129 The Implementation of EPP Software using HIV Prevalence Data from Studies Conducted in Greece

Georgios Nikolopoulos (1) * Chryssa Tsiara (1) Chryssoula Botsi (1)

(1) Hellenic Centre For Diseases Control And Prevention , Amarausio, Greece

P-130 HIV/AIDS Related Knowledge and Attitude among Female Sex Workers in Tehran/Iran

Saeid Madani Ghahfarokhi (1) * Ameneh Setareh Forouzan (1) Payam Roshanfekar (1, 1, 1) Mohamad Ali Mohammadi (1) Masoumeh Dejman (1) Meroeh Vameghi (1) Mirtaher Mousavi (1) Hassan Rafiee (1) Mansoureh Hemmasian Etefagh (1) Malihe Sheyani (2)

(1) Social Welfare and Rehabilitation Sciences University, Tehran, Iran, Islamic Republic of (2) social sciences department, , Tehran, Iran, Islamic Republic of

P-131 HIV Sero-Prevalence, Knowledge and High Risk Behaviour in Specific Population Groups in Ludhiana, India

Benjamin Anoop Ivan (1) * Singh Shavinder (1) Sengupta Paramita (1) Dhanoa Jasbir (1)

(1) Christian Medical College, Ludhiana, India

P-132 CANCELLED

P-133 Problem of Nosocomial Infection with Hepatitis B, C Viruses and HIV in Russian Dental Institutes. Review.

alexey shatokhin (1) *

(1) City AIDS Center, Moscow, Russian Federation

P-134 Feto-Maternal Outcomes in HIV Positive Pregnant Women: Pakistan PPTCT Experience

shazra abbas (1) * naveeda shabbir (1)

(1) National AIDS Control program pakistan, Islamabad, Pakistan

P-135 An Analysis of Non Response in HIV Testing in India: Evidences from National Family Health Survey -3

Shri Kant Singh (1) *

(1) International Institute for Population Sciences, Mumbai, India

P-136 The Evaluation of Peer Education Workshops Efficacy on Knowledge of Non Medical Students About HIV/AIDS , Bushehr, South of Iran
Hesam_oddin Maneshi (1) * Ismaeil Asaadi (1)

(1) Bushehr University of Medical Sciences - Student's Research Committee, Bushehr, Iran, Islamic Republic of

P-137 Determinants Of the Willingness-To-Pay For HIV/AIDS Prevention: The Case Of Mother-To-Child Transmission In Selected Hospitals In Ghana
Emmanuel Ayifah (1) *

(1) University of Ghana, Accra, Ghana

P-138 Knowledge and Attitudes of Students in an Offshore Caribbean Medical School Towards HIV/AIDS
Rotimi Orisatoki (1) * Oluwafemi Oguntibeju (1, 1)

(1) Spartan Health Sciences University, School of Medicine, Vieux Fort, Saint Lucia(2) Cape Peninsula University of Technology, Bellville 7535, South Africa

P-139 Creating a Supportive Environment is Very Important to Reduce STI, HIV/AIDS and Infectious Disease.
S.M Rezaul Islam (1) * Nahida Islam (1)

(1) SHED Foundation, Chittagong, Bangladesh

P-140 Civic Educating Rural Pregnant Mothers to Take Full Nevaripine Dose a Tool to Reducing HIV Prevalence in Malawi
Caleb Kondwani Faith Thole (1) *

(1) Global Hope Mobilization, Lilongwe, Malawi(2) International AIDS Society, Geneva, Switzerland(3) Equinet, Southern Africa, Zimbabwe

P-141 A Study of HIV/AIDS Related Knowledge and Attitudes amongst the Engineering College Students
Arijit Kumar (1) * Pankaj Bharadwaj (1) J.P Srivastava (1)

(1) Eras Lucknow Medical College And Hospital, Lucknow, India

P-142 Services Integration for Injection Drug Users on Antiretroviral Therapy for Management of HIV Epidemic in Estonia
Kaja-Triin Laisaar (1) * Anneli Uusküla (1) Anjali Sharma (2) Jack DeHovitz (2)

(1) Department of Public Health, University of Tartu, Tartu, Estonia(2) Downstate Medical Center, State University of New York, Brooklyn, United States of America

P-143 The International Physical Activity Questionnaire Overestimates Moderate and Vigorous Physical Activity in Human Immunodeficiency Virus Compared with Accelerometry
Soula Fillipas (1, 2) * Flavia Cicuttini (1, 2) Catherine Cherry (1, 2, 3) Anne Holland (1, 4)

(1) The Alfred, Melbourne, Australia(2) Monash University, Melbourne, Australia(3) Burnet Institute, Melbourne, Australia(4) La Trobe University, Bundoora, Australia

P-144 The Perception of Taxi Drivers in Southern Part of Saint Lucia, West Indies Towards HIV/AIDS and Condom Use
Rotimi Orisatoki (1) * Oluwafemi Oguntibeju (2)

(1) Spartan Health Sciences University, School of Medicine, Vieux Fort, Saint Lucia(2) Cape Peninsula University of Technology, Bellville 7535, South Africa

P-145 Interventions and Strategy to Mitigate HIV Related Risk Behavior Among Young Men in India
Vipul Vipul (1) * Srikant Srikant (1)

(1) IIPS, Mumbai, India

P-146 Increased Antenatal HIV Testing among Rural Pregnant Women: a Community-Based HIV Prevention Services Program in Rural Maharashtra, India.

Ashok Dyalchand (1) * Gita Sinha (1)

(1) Institute of Health Management Pachod , Pune , India

P-147 Effect of Materials on HIV/AIDS by the Different Segment of Population in a Selected Community Area.

Rezaul Karim (1) *

(1) NIPSOM, DHAKA, Bangladesh

P-148 Assessing Risk Criteria and HIV Prevalence in Antenatal Clinic Clients from 2 Urban Tertiary Hospitals in Pakistan

Naveeda Shabbir (1) * Qudsia Uzma (1) Shazra Abbass (1)

(1) National AIDS Control Programme, Islamabad, Pakistan

P-149 Develop IEC Material by PLHA to Lead a Positive Life.

Santosh Chettri (1) *

(1) National Association of People living with HIV/AIDS in Nepal (NAP+N), Kathmandu, Nepal

► **C2: Hepatitis, Epidemiology & Prevention**

P-150 Service Integration of Blood Borne Viral Infections in HIV/AIDS Prevention Sites

Steven McCadney (1) *

(1) Yeshiva University, New York City, United States of America

P-151 HBV and HCV Viral Markers Seroprevalence in First-Time Healthy Blood Donors Referred to Transfusion Centers of Bushehr Province, South of Iran (April2004 to March2008)

Hesam_oddin Maneshi (1) * Shahab Zare (1) Mojtaba Karimi (2) Gholam Reza Hajiani (2)

(1) Bushehr University of Medical Sciences - Student's Research Committee, Bushehr, Iran, Islamic Republic of(2) Bushehr Blood transfusion organization, Bushehr, Iran, Islamic Republic of

P-152 Protecting at Risk Cadres of Health Workers from Medical Transmission of HIV and Hepatitis B and C Through Injection Safety Interventions

Susana de la Torre (1) * Deepa Bhat (1) Jessica Posner (1) Megan Noel (1) Victoria Masembe (2) Jackson Songa (3) Iqbal Hossain (1)

(1) John Snow Inc., Arlington, United States(2) John Snow Inc., Kampala, Uganda(3) John Snow, Inc., Nairobi, Kenya

P-153 Awareness about Hepatitis B Infection among the Grass Root Level Health and Family Planning Workers in a Selected Health Complex at Dhaka District.

Rezaul Karim (1) *

(1) NIPSOM, Dhaka, Belarus

P-154 Seroprevalence of Hepatitis B-Surface Antigen Among Selected Group of Population

Rezaul Karim (1) *

(1) NIPSOM, Dhaka, Bangladesh

► C3: Other, Epidemiology & Prevention

P-155 Home Visiting to an HIV Positive Patient Prior to Initiation of Haart Has Lasting Impact on Their Adherence. Taso Experience.

Emmanuel Odeke (1) * Ricky Jones Nyatia (1, 1) Peter Sekiranda (1, 1)

(1) *The AIDS Support Organisation (TASO), Kampala, Uganda*

P-156 Prevention by Care and Treatment of HIV-Positive Pregnant Woman in Côte D'ivoire

Kouamé Hervé Aka Prao (1) * Nicole Dakoury (1, 1) Pety Touré (1, 1) Nafissa Diakité (1) Koko Régina Konan (1) Marie-france Coulibaly Anaky (1) Siaka Touré (1, 1) Irma Ahoba Bobo (2)

P-157 A Model to Determine Effective HIV/AIDS and Multi-Drug Tuberculosis (MDRTB) Treatment Policies: A Case Study from the Russian Federation

Reda Lebcir (1) *

(1) *University of Hertfordshire, Hatfield, United Kingdom*

P-158 Sexual Behaviours and Drug Use among the Street Children

Shyam Lamsal (1) *

(1) *B.P.Koirala Institute of Health Sciences, Dharan, Nepal*

P-159 Hospitalization Potential at an Infectious Diseases Division of a Metropolitan Hospital of Northern Italy. Persisting Limitations and Related Problems

Roberto Manfredi (1) *

(1) *Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy*

P-160 HIV/AIDS and Human Rights in Legislation of the Republic of Serbia

Miljana Grbic (1) * Vojin Dimitrijevic (2) Nenad Petkovic (3) Ana Maricic (4) Judita Reichenberg (5) Jelena Zajeganovic (5) Milos Stojanovic (1) Rade Grbic (6)

(1) *UNAIDS, Belgrade, Serbia*(2) *Beogradski centar za ljudska prava, Belgrade, Serbia*(3) *Q-klub, Belgrade, Serbia*(4) *Ministry of Justice, Belgrade, Serbia*(5) *UNICEF, Belgrade, Serbia*(6) *Medical Faculty Pr, Pristina, Serbia*

P-161 Supporting Homeless People Living with HIV

Ailsa Cameron (1) *

(1) *University of Bristol, Bristol, United Kingdom*

P-162 Difficulties to Implement a Support Group for HIV Patients

Julia Artur (1) * Philippe Genet (1) Agathe Pigeon (1) Tahar Touarhi (1)

(1) *CH Argenteuil, Argenteuil, France*

D Pharmacology

► D1: HIV, New Drugs

P-163 Allosteric Regulation by Non Peptidic, Low Molecular Weight Compounds of CCR5 Coupling to G-Proteins and Interaction with GP120 - Consequences on Inhibition of R5 HIV-1 Infection.

Patricia Rueda (1) * Javier Garcia-Perez (1, 2) Isabelle Staropoli (1) Esther Kellenberger (3) José Alcamí (2) Fernando Arenzana-Seisdedos (1) Bernard Lagane (1)

(1) *Institut Pasteur, Paris, France*(2) *Instituto de Salud Carlos III, Madrid, Spain*(3) *Université Louis Pasteur, Strasbourg, France*

P-164 Modulations of Human Placental Transfer of Lopinavir, Ritonavir and Enfuvirtide.

Pierre-François Ceccaldi (1, 2, 3) * Laurent Mandelbrot (3) Claudia Ferreira (3) Robert Farinotti (1) Francois Forestier (1) Sophie Gil (1)

(1) Department of Clinical Pharmacy, University Paris-Sud 11, IFR141, School of Pharmacy, Châtenay-Malabry, France(2) Department of Obstetrics and Gynecology, Beaujon Hospital, AP-HP, Clichy, France(3) Department of Obstetrics and Gynecology, Louis Mourier Hospital, AP-HP, Colombes, France

P-165 Pharmacological Profiling of Novel HIV-1 Protease Inhibitors as Effective P-Glycoprotein Inhibitors for Combined Antiretroviral Therapies

Claudius Coburger (1) * German Erlenkamp (1) Wolfgang Sippl (1) Christiane Baumert (1) Hermann Lage (3) Joséf Molnár (2) Andreas Langner (1) Andreas Hilgeroth (1)

(1) Martin Luther University, Halle, Germany(2) University of Szeged, Szeged, Hungary(3) University Hospital Charité, Berlin, Germany

P-166 Duration of Antiretroviral Regimens in Treatment-Experienced Patients in Clinical Practice

Vicente Escudero Vilaplana (1) * Sergio Plata Paniagua (1) Nicolas Trovato Lopez (1) Isabel Castillo Romera (1) Arantza Ais Larisgoitia (1) Jose Maria Bellon Cano (1) Maria Sanjurjo Saez (1)

(1) Hospital General Universitario Gregorio Marañón, Madrid, Spain

► **D3: Therapeutic Drug Monitoring**

P-167 A Model Using Adherence: House Compliance Center Oasis AAS

Abdoulazziz Soundiata Traoré (1) *

(1) Association African Solidarité, Ouagadougou, Burkina Faso

E Emerging Infectious Diseases

► **E1: Laboratory Aspects**

P-168 Scorpion Model of Influenza A/H1N1: Hemagglutinin (Ha) Contains A Scorpion Toxin, Binding To Voltage-Gated Sodium Na⁺ Channel: Na⁺ Channel Inhibitors as Therapy.

Guy Mong Ky Tran (1, 2) * Laurent Gerbaud (1) Adrien Caprani (2)

(1) University of Auvergne, Hotel-Dieu Hospital, Clermont-Ferrand, France(2) Association POSITIFS, Paris, France

P-169 Development of a Test System for Simultaneous Detection of HIV RNA and Hepatitis C Virus (HCV) and DNA of Hepatitis B Virus (HBV) in Blood Samples

Nader Shahrokhi (1) * Masoud Hajia (2) Maysam Shahrokhi (2) Foroozan Abbasi (2) Mohamad Farzaneh-Khah (2)

(1) Pasteur Institute of Iran, Tehran, Iran, Islamic Republic of(2) Noor Medical Laboratory, Tehran, Iran, Islamic Republic of

P-170 Analyses Reveal a Novel Avirulent Streptococcus Suis Serotype 2 Strain that Induces Protective Immunity Against Challenge with the Highly Virulent Strains

Jiaqi Tang (1) *

(1) Department of Epidemiology, Research Institute for Medicine of Nanjing Command, Nanjing, China

P-171 A Prospective Project of Microbiological Surveillance at a Teaching Hospital in Italy. Evolving Epidemiological Features, and in vitro Antimicrobial Sensitivity Trends

Roberto Manfredi (1) *

(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy

P-172 A Prospective Microbiological Surveillance in a Teaching Italian Hospital. Microbial Isolations and in vitro Antimicrobial Susceptibility Levels, and their Modifications Over Time

Roberto Manfredi (1) *

(1) Infectious Diseases, University of Bologna, Bologna, Italy

P-173 Auto-Immune Thrombocytopenia after Measles Mumps Rubella MMR Vaccination: Molecular Mimicry of Measles Virus Phosphoprotein with Platelet GPIIB.

Guy Mong Ky Tran (1, 2) * Laurent Gerbaud (1) Adrien Caprani (2)

(1) University of Auvergne, Hotel-Dieu Hospital, Clermont-Ferrand, France(2) Association Positifs, Paris, France

P-174 Urinary Tract Pathogens Among Inpatients at a Large Italian Tertiary Care Hospital. A Prospective Monitoring Study

Roberto Manfredi (1) *

(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy

P-175 Agents Causative of Sepsis-Bacteremia in a Four-Year Prospective Surveillance Study Carried Out at a Teaching Italian Hospital

Roberto Manfredi (1) *

(1) Infectious Diseases, University of Bologna, Bologna, Italy

► **E2: Clinical Aspects**

P-176 The Emerging and the Spread of the Fifth Plasmodium Responsible of Human Malaria: Plasmodium Knowlesi

Roberto Manfredi (1) * Sergio Sabbatani (1) Sirio Fiorino (1, 2)

(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy(2) Department of Internal Medicine, Budrio, Italy

P-177 Perceived Quality of Clinical Care Provided by Nurses to People Living with HIV at Four Taso Sites in Uganda

Kenneth Mugisha (1, 2) * Coutinho Alex (2)

(1) TASO, Kampala, Uganda(2) IDI, Kampala, Uganda

P-178 An Increasing Pathomorphism of Pulmonary Tuberculosis. Is There a Therapeutic Role for Novel Antimicrobial Compounds Effective on Mycobacterium Tuberculosis?

Roberto Manfredi (1) * Sergio Sabbatani (1) Leonardo Calza (1)

(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy

P-179 Symptomatic, Prolonged Parvovirus B19 Infection and Accompanying Illness in Otherwise Healthy Adults

Roberto Manfredi (1) *

(1) Infectious Diseases, University of Bologna, Bologna, Italy

P-180 An Infectious Disease Day-Hospital Service in a Metropolitan Area of Northern Italy. Evolving Assistance Features in the Last Fifteen Years (1994-2008)

Roberto Manfredi (1) *

(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy



► E4: Other, Emerging Infectious Diseases

P-181 Is There Pre-Existing Cross-Reactivity to Influenza A(H1N1)2009 in a Tropical Population?
Kwai Peng Chan (1) * Yee Leng Lee (1) Xin Lai Bai (1) Siew Hoon Lim (1)

(1) Singapore General Hospital, Singapore, Singapore

P-182 Molecular Epidemiology of Chikungunya Strains in Singapore in 2008
Kim-Yoong Puong (1) * Kwai-Peng Chan (1)

(1) Singapore General Hospital, Singapore, Singapore

P-183 Synthesis of the Studies About the Transmission Cycle of Malaria in an Area of Very Low Incidence Outside the Amazon Region in Brazil
Crispim Jr Cerutti (1) * Aloísio Falqueto (1) Helder Ricas Rezende (4) Renata Soares (2) Isabel Alves (2) Delsio Natal (2) Paulo Roberto Urbinatti (2) Tasciane Yamasaki (2) Ana Maria Ribeiro de Castro Duarte (3) Rosely dos Santos Malafronte (2)

(1) Universidade Federal do Espírito Santo, Vitória, Brazil(2) Universidade de São Paulo, São Paulo, Brazil(3) Superintendência de Controle de Endemias, São Paulo, Brazil(4) SESA, Vitória, Brazil

P-184 Clinical Presentation of Influenza A (H1N1) Infection in a Local Emergency Department in Greece.

Evangelos Voudoukis (1) Athanasios Panoutsopoulos (1) Pappas Apostolos (1) Stofa Efthimia (1) Leventogianni Vassiliki (1) Mpoumpoukas Theodoros (1) Mylona Panagiota (1) Rozi Fotini (1) Andrianopoulos Ioannis (1) Andrianopoulos Georgios (1) *

(1) Department of internal medicine of General Hospital of Argos, argos, Greece

P-185 Comparison Of A Novel Real-Time RT-PCR, NS1 Antigen Detection And Serology In Early Diagnosis Of Dengue In Travelers.

Eili Huhtamo (1) *

(1) University of Helsinki, Helsinki, Finland

P-186 Influence Of Water On The Circulation Of The West Nile Virus In Horses In Southern France
Sophie Pradier (1, 2) * Alain Sandoz (3) Gaëtan Lefebvre (3) Annelise Tran (4) Sylvie Lecollinet (5) Agnès Leblond (2, 6)

(1) Clinique équine ENVA, Maisons-Alfort, France(2) UR 346 Epidémiologie animale INRA, Saint Genès Champanelle, France(3) Tour du Valat, Arles, France(4) CIRAD Agirs, Montpellier, France(5) UMR 1161 Virologie INRA AFSSA ENVA, Maisons-Alfort, France(6) Clinéquine ENVL, Marcy l'étoile, France

P-187 An Outbreak Of Influenza A (H1N1) 2009 At Mae Fah Luang University, Chiang Rai Province, Northern Thailand

Tawatchai Apidechkul (1) *

(1) Mae Fah Luang University, Chiang Rai Province, Thailand

P-188 Adherence To The Treatment Of Individuals With The HIV/Tuberculosis Co-Infection: Integrative Review

Lis Neves (1) Renata Reis (2) Elucir Gir (1) * Patrícia Ribeiro (1)

(1) São Paulo University - School Of Nursing De Ribeirão Preto , Ribeirão Preto, Brazil(2) Alagoas University, Maceió, Brazil

P-189 HIV & Emerging Infectious Diseases In Mobile Populations In Europe
Anna-Paola de Felici (1) * Manuel Carballo (1) Sofiat M.Akinola (1)

(1) International Centre for Migration, Health and Development, Geneva, Switzerland

P-190 Serum Levels Of Inflammatory Cytokines In Leprosy Patients

Lúcia de Paula (1) * Isabella Motta Passos (1) Rossilene Conceição da Silva (1) Adriana Malheiro (2)
George Allan Villarouco Silva (1) Máisa Porto dos Santos (1) Maria da Graça Souza Cunha (1)

(1) Fundação Alfredo da Matta, Manaus, AM, Brazil (2) Fundação de Hematologia e Hemoterapia do Amazonas, Manaus, AM, Brazil

P-191 Detection Of Ovine Herpesvirus-2 In Swine Semen, Brazil

Erica Azevedo Costa (1) * Aline de Marco Viott (1) Glauber de Souza Machado (1) Maria Rosa Quaresma Bomfim (1) Fabiana Magalhães Coelho (1) Mauricio Resende (1) Roberto Mauricio Carvalho Guedes (1)

(1) Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

P-192 Multiple, Concurrent Or Subsequent Dysreactive And Autoimmune Disorders. Potential Clinical-Patogenetic Correlations, And Systemic Infectious Complications

Roberto Manfredi (1) *

(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy



ISHEID organization / Isheid 2010, organisation du congrès

c/o Colloquium Paris

12 rue de la Croix-Faubin

75557 Paris cedex 11

France

E-mail : isheid@clq-group.com

Ph. +33 (0)1 44 64 15 15 - Fax : +33 (0)1 44 64 15 16

Venue and Dates / Dates et lieux du congrès

16th ISHEID congress will be held from Wednesday 24 March to Friday 26 March 2010 and will take place at : / Le 16eme congrès ISHEID sur le VIH et les maladies infectieuses émergentes se tiendra du mercredi 24 mars au vendredi 26 mars 2010 au :

Parc Chanot, Marseille Congress Centre / Parc Chanot de Marseille

Parc Chanot Safim - BP 2 - 13266 Marseille Cedex 08

For more information : / Pour plus d'information : www.parc-chanot.com

Access to the Parc Chanot / Accès au Parc Chanot

► By car / En voiture :

Motorway / Autoroute **Noth A7** : Lyon, Paris, Bruxelles

Motorway / Autoroute **Littoral A55** : Arles, Montpellier, Toulouse, Barcelone.

Motorway / Autoroute **East A50** : Toulon, Nice, Milan, Turin, Gènes

► By train / En train :

Marseille Saint Charles TGV station, located in the heart of Marseille, the station gives a direct access by metro to the Parc Chanot (5 stations). / **Gare TGV Marseille Saint Charles**, située au coeur de Marseille, la gare permet un accès direct par métro jusqu'au Parc Chanot (5 stations).

► Taxi from station / Taxi gare :

Tel : +33 (0)4 91 02 20 20

► By metro / En métro :

From Saint Charles station : 13 minutes. Direction : **Sainte Marguerite**.

A partir de la Gare Saint Charles : 13 minutes. Direction : **Sainte Marguerite**.

Exit station « Rond Point du Prado ». More information : www.rtm.fr

Sortie station « Rond Point du Prado ». Pour plus d'information : www.rtm.fr

► By plane / En avion :

International Marseille Airport - Provence is 30mn from Marseille city centre.

Aéroport International Marseille - Provence à 30 mn du centre ville de Marseille.

Information (24h/24h) : Tel : +33 (0)4 42 14 14 14/ +33 (0)4 42 14 21 14

► Bus connexions / Liaisons Bus : Airport - St Charles station / Aéroport - Gare St Charles, information : Tel : +33 (0)4 42 14 31 27/+33 (0)4 91 50 59 34

► Shuttle every 20 mn from 6h10 to 22h50 / Navettes toutes les 20 mn de 6h10 à 22h50

Taxis airport / Taxis aéroport : +33 (0)4 42 14 24 44 /+33 (0)4 42 88 11 44

Registration / Inscriptions

► For registration, please register on-line on www.isheid.com /
Inscrivez-vous en ligne sur www.isheid.com

► Registration fees for delegates include: Admission to all congress sessions, poster area and technical exhibition, Congress documents, and coffee breaks/ Le montant des droits d'inscription inclut : la participation aux sessions du Congrès, aux présentations Posters et à l'exposition commerciale ainsi que les documents du congrès.

* All the above rates are in Euros, French VAT 19.6% included / Montants exprimés en Euros, TVA française à 19,6% incluse.

** Reduced rate applicable to the following categories: AIDS Association

Registration & payment*	Before 15/01/10	From 16/01/10 to 15/03/10	On-site
Participant	355 €	400 €	460 €
Reduced rate**	90 €	100 €	110 €
Group rate		340 €	

Member, Students/Residents (please send a copy of your student card), Low and Middle income countries (World Bank List <http://go.worldbank.org/K2CKM78CCO>), Nurses

Important dates / Dates importantes Registration / Inscriptions

End of preferential rate 25 January 2010 / Tarif préférentiel applicable jusqu'au : 25 janvier 2010

End of regular rate 14 March 2010 / Tarif normal applicable jusqu'au : 14 mars 2010

Congress opening / Ouverture du congrès : Wednesday 24 March 2010 / mercredi 24 mars 2010

Group registrations / Inscriptions groupe

(for groups of 10 participants or more / pour des groupes de 10 participants ou plus)

Unique rate: 340 € for all participants (subjected to conditions) /

Tarif unique : 340 € (tarif soumis à conditions).

For information on / Pour plus d'informations sur :

Terms of payments, Cancellation policy for individual registrations, SNCF & Air France reduction, access to conference centre, CME credits.../ Conditions de paiement, conditions d'annulations pour les individuels, réductions SNCF & Air France, accès au centre de conférence, accréditation CME...

Please refer to the congress website for full information. /

Merci de vous rendre sur le site officiel du congrès.

Accommodation / Hébergement

WIP is the official hotel reservation centre in charge of accommodation for the 2010 ISHEID Congress. /
WIP est la centrale de réservation hôtelière officielle pour la gestion de l'hébergement du congrès ISHEID 2010.

To book your room on-line go to http://www.wipresa.net/wipresa/congres_isheid

Pour faire votre réservation hôtelière, veuillez aller sur : http://www.wipresa.net/wipresa/congres_isheid

**SPONSORS
PARTENAIRES**

SILVER SPONSORS / PARTENAIRE ARGENT

ABBOTT FRANCE
BRISTOL-MYERS SQUIBB
GILEAD
LABORATOIRES MERCK SHARP & DOHME-CHIBRET
SCHERING PLOUGH
TIBOTEC / JANSSEN CILAG

BRONZE SPONSORS / PARTENAIRE BRONZE

BOEHRINGER INGELHEIM
LABORATOIRE GLAXOSMITHKLINE

SPONSORS / PARTENAIRES

CELLESTIS
WISEPRESS
ROCHE